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MS is a heterogeneous disease characterized by transient and later permanent disability 
caused by inflammatory CNS lesions with profound axonal loss and demyelination. Although 
the exact pathogenesis of the disease is still unknown, it is assumed that MS is an 
autoimmune disease. While earlier concepts focused on the role of T cells, B cells are 
increasingly recognized to play an important role. The fumaric acid ester DMF is an 
immunomodulatory agent which is approved for the therapy of relapsing-remitting MS. In 
MS patients, DMF effectively reduces the relapse rate as well as the number and extent of 
MRI lesions. DMF shows anti-inflammatory properties by modulating immune cell functions 
leading to a decrease in pro-inflammatory cytokine production. Furthermore, DMF may 
exert neuroprotective effects in part mediated by the induction of Nrf2 resulting in the 
activation of antioxidant response pathways. In our study, we investigated whether DMF has 
neuroprotective and/or neuroregenerative function independent of its effect on the 
peripheral immune system. For this purpose, DMF effects were studied in a setting of toxic 
demyelination, namely the cuprizone model. In the second part of our study, it was also 
analyzed to what extent DMF influences pathogenic B cell and T cell properties in in an EAE 
model, in which B cells are involved in a pathogenic manner.  
Regarding the first part of the project, we found that DMF significantly diminished the 
cuprizone-induced apoptosis of oligodendrocytes and increased the number of 
oligodendrocytes over time during cuprizone intoxication. Upon short-term cuprizone 
exposure, DMF increased the number of oligodendrocyte progenitor cells (OPCs) whereas 
after long-term cuprizone diet higher numbers of mature oligodendrocytes could be 
observed. Although DMF treatment did not influence demyelination and remyelination of 
the corpus callosum, acute axonal damage was significantly decreased in DMF treated mice. 
In conclusion, DMF was found to exert moderate neuroprotective and neuroregenerative 
effects independent of the peripheral immune system. The observation of higher OPC 
numbers in conjunction with a higher number of mature oligodendrocytes after long-term 






In the second part, preventive as well as therapeutic DMF treatment was effective in 
a B cell-mediated EAE model. Clinical benefit of DMF treatment in mice with established EAE 
was associated with decreased demyelination and inflammation of the spinal cord. The 
infiltration of macrophages/microglia and partially also of T cells was reduced by DMF 
treatment, whereas DMF had no detectable effect on the number of infiltrating B cells. In 
peripheral compartments, DMF led to a lower T cell frequency in the blood, while a 
complementary accumulation of T cells could be observed in lymph node and spleen of 
DMF-treated mice with EAE. Besides its effect on T cell frequencies, DMF treatment 
significantly reduced activation, differentiation and proliferation of peripheral T cells. In 
contrast, DMF-treatment exerted no inhibitory effect on peripheral B cells and caused an 
enhanced activation and differentiation of B cells. Most persistently, we observed an 
upregulation of MHC II on B cells. Functionally, these alterations were associated with an 
enhanced capacity of B cells to act as antigen presenting cells for activation of T cells. In 
conclusion, the observed clinical and pathological benefit in EAE with pathogenic B cell 
function thus appears to be mediated by an immunomodulatory effect of DMF directly on T 
cells. Contrary, we found that DMF treatment promoted antigen-presenting properties of 
B cells, while this study could not conclusively reveal which T cell phenotype is induced by 
these more potent B cells. Nevertheless, the primary observation of an enhanced B cell 
activation and antigen presenting function upon DMF treatment might be of significant 
relevance in specific therapeutic decisions, such as choosing the appropriate MS medication 
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1.1. Multiple Sclerosis 
Multiple sclerosis (MS) is the most common autoimmune disease of the central nervous system 
(CNS) with approximately 2.5 million affected people worldwide (healthline.com/health/multiple-
sclerosis/facts-statistics-infographic). MS is most commonly diagnosed in adults in their late 
twenties or early thirties. The clinical characteristics and pathology of MS were first described by 
Robert Carswell in 1838, who described and illustrated lesions of the spinal cord. The pathological 
hallmarks of MS lesions are inflammation, demyelination, gliosis and axonal loss (Brück and 
Stadelmann, 2003). The inflammation is caused by microglia and infiltrating macrophages, T cells 
and B cells.  Despite that MS was mainly described as a T cell-driven disease, growing evidence 
suggests that B cells play an important role in the pathogenesis of the disease (Weber et al., 2010; 
Franciotta et al., 2008). 
1.1.1. Symptoms, clinical course and diagnosis 
MS is associated  with a large variety of symptoms, like vision loss (partly or complete), changed 
sensation in arms or legs as well as fatigue and impairment of balance (Smith and McDonald, 
1999). The symptoms can be transient but may also persist. 
In 1996 the US National Multiple Sclerosis Society (NMSS) Advisory Committee on Clinical Trials in 
Multiple Sclerosis described 4 phenotypes of MS: relapsing-remitting (RRMS), secondary 
progressive (SPMS), primary progressive (PPMS), and progressive relapsing (PRMS) (Lublin and 
Reingold, 1996). The definition of these subtypes was revised in 2013 and the clinical isolated 
syndrome (CIS) and the radiologically isolated syndrome (RIS) were added as new subtypes (Lublin 
et al., 2014). The progressive relapsing phenotype was removed since those patients would now 
be categorized as PPMS patients with superimposed relapses and/or MRI activity.  
RRMS occurs in about 85% of patients and is therefore the most common subtype of MS 
(Weinshenker, 1998). The characteristics of RRMS are disease relapses with full recovery or 
remaining deficits after partial recovery. Relapses are defined by an acute worsening of disease 
over a short period of time, which is often followed by a varying degree of remission. The clinical 
course remains stable between relapses. Typical symptoms of RRMS are sensory dysfunctions, 





progresses continuously between relapses, the RRMS patient has converted to a secondary 
progressive phenotype. Approximately 70% of RRMS patients develop a SPMS after about 20 years  
(Weinshenker, 1998). 
SPMS is defined by a steady progression of disease after an  initial relapsing-remitting disease 
course and rarely by additional occasional relapses with minor recovery (Lublin and Reingold, 
1996). 
The small proportion of MS patients who do not display the characteristics of RRMS or SPMS show 
the phenotype of PPMS. PPMS is characterized by a continuous disease progression from onset. 
Disease plateaus or minor improvements can occur over time. PPMS affects approximately 10-15% 
of MS patients and the disease onset is about 10 years later compared to RRMS (Miller and Leary, 
2007; Ontaneda and Fox, 2015; Thompson et al., 1997). The most important difference between 
RRMS and PPMS is how fast symptoms develop. In RRMS, new neurological deficits occur within 
days, but symptoms can resolve quickly. PPMS, in contrast, is characterized by accumulating 
disability over months and years and symptoms do not regress.  Patients with PPMS often suffer 
from a progressive myelopathy which can emerge as a spastic, atactic paresis with dysfunction of 
the annular muscle (Ontaneda and Fox, 2015).  
Nowadays, MS is diagnosed by application of the McDonald criteria (McDonald et al., 2001), which 
were first described in 2001 and revised in 2005 and 2010 (Polman et al., 2005, 2011). Following 
these criteria, MS is diagnosed after consideration of the clinical symptoms, MRI data and 
cerebrospinal fluid parameters (e.g. oligoclonal IgG bands). MRI criteria support an accurate 
diagnosis by depicting dissemination of lesions in time and space and thereby assist to exclude 
disorders which can mimic clinical and laboratory aspects of MS (Filippi et al., 2016). The European 
collaborative research network that studies MRI in MS (MAGNIMS) recommended in 2016 






Table 1: The new 2016 MAGNIMS MRI criteria (modified from Radiopedia.org)  
Dissemination in space 
(established by two of five following areas) 
Dissemination in time 
(established by one of two ways) 
• cortical-juxtacortical: ≥1 lesions  
• infratentorial: ≥1 lesions 
• optic nerve: ≥1 lesions 
• periventricular: ≥3 lesions 
• spinal cord: ≥1 lesions 
• a new lesion when compared to a previous 
scan (irrespective of timing)  T2 bright lesion 
and/or gadolinium-enhancing 
• presence of enhancing lesion and a non-
enhancing T2 bright lesion on any one scan 
 
1.1.2. Pathogenesis and Pathology  
1.1.2.1. MS Pathogenesis 
Based on results which were found in experimental autoimmune encephalomyelitis (EAE), an 
animal model of MS, it is assumed that peripheral immune cells cause an pro-inflammatory 
response in the CNS (Hemmer et al., 2015). T cells are assumed to be the cells activated first, 
which infiltrate the prior unaffected CNS tissue. The infiltrating auto-reactive T cells release pro-
inflammatory cytokines like TNF-α and IFNγ which trigger an increased release of other cytokines 
and chemokines (e.g..: CCL3, CCL5, CXCL8, CXC3L1) (Larochelle et al., 2011). As a result of this 
inflammatory condition, endothelial cells (ECs) of the blood brain barrier (BBB) become activated 
and their expression of cell adhesion molecules (CAMs) increases (Bartholomäus et al., 2009). This 
process leads to the attraction of additional immune cells, including monocytes, B and T cells, 
plasma cells and dendritic cells which numerously invade the CNS tissue. The resulting 
inflammation interferes with the astroglial and oligodendroglial homeostasis. The infiltrating 
plasma cells produce antibodies which might lead to the damage of glial cells and the myelin 
sheath (Hemmer et al., 2015). Microglia and macrophages can cause axonal damage and injure the 
myelin by release of reactive oxygen and nitrogen species (ROS) (Fischer et al., 2012). The 
interaction of those macrophages/microglial cells and lymphocytes leads to the formation of an 
inflammatory phagocytic lesion. The initiation of the disease by T cells, however, is just one of the 





As newly forming MS lesions are associated with large numbers of activated microglia and only 
few infiltrating lymphocytes, an alternative hypothesis suggests that local CNS inflammation 
causes lesion formation (Barnett and Prineas, 2004; Henderson et al., 2009).  
1.1.2.2. Pathology 
Demyelination, inflammation, gliosis and axonal damage are the pathological hallmarks of MS 
(Kuhlmann et al., 2002). MS plaques (focal white matter lesions) can be present all over the CNS 
with predominant occurrence in the spinal cord, optic nerve, periventricular areas and brain stem 
(Stadelmann et al., 2011). Active plaques, defined by minor and major myelin protein degradation 
products within macrophages, most frequently arise in early disease stages, whereas smoldering 
(slowly expanding), inactive or shadow plaques are more prominent in chronic disease stages 
(Frischer et al., 2015). Inactive lesions show a sharp border and no or few macrophages and 
activated microglia. White matter lesions which are completely remyelinated are the so-called 
shadow plaques (Barkhof et al., 2003; Patrikios et al., 2006). Active lesions are more pronounced 
in RRMS patients but also occur in lower numbers in progressive MS. Smoldering plaques are 
characterized by an inactive center containing few macrophages but activated microglia are still 
present. These lesions seem to be characteristic of progressive MS, as they are exclusively found in 
progressive disease courses. Furthermore, patients with PPMS or SPMS show a higher frequency 
of cortical lesions and the injury of the normal-appearing white matter (NAWM) is more 
pronounced compared to RRMS patients (Kutzelnigg et al., 2005). It is characterized by a diffuse 
inflammation and axonal injury in non-demyelinated areas.  
Early and chronic MS lesions differ in the extent of inflammatory cell infiltrates, demyelination and 
axonal damage (Brück et al., 1995; Kuhlmann et al., 2002, 2008a). Early lesions are characterized 
by a dominant accumulation of macrophages filled with myelin degradation products, a variable 
density of T cells in perivascular and parenchymal tissue, varying numbers of B cells and plasma 
cells, sometimes incomplete demyelination and a pronounced acute axonal damage. In chronic MS 
lesions only few lymphocytes and phagocytic cells are present, mature oligodendrocytes are often 
reduced, whereas oligodendrocyte precursor cells (OPC) may still be present. A pronounced 
reduction in the axonal density is especially found in lesions of MS patients, but also occurs in the 
NAWM (Evangelou et al., 2000; Tallantyre et al., 2009). The extent of remyelination is more 





Early active MS lesions represent early stages of lesion formation. In those lesions, four different 
patterns of demyelination can be differentiated that are defined by the loss of myelin proteins, 
extent of oligodendrocyte destruction, extension and localization of plaques and evidence of 
immunoglobulin and complement deposition (Lucchinetti et al., 2000).  
Pattern I lesions are characterized by active demyelination accompanied by a prominent T cell- 
and macrophage-associated inflammation. The myelin protein loss in pattern I is evenly 
distributed and the lesions show sharply demarcated edges.   
MS pattern II is similar to pattern I, but additionally shows deposits of immunoglobulins (Ig) and 
complement C9neo antigens. As these hallmarks are most prominent at sites of active 
demyelination and within phagocytic cells, it has been suggested that the myelin injury in this 
pattern could be mediated by the humoral immune system. 
MS pattern III and pattern IV lesions also show inflammatory infiltrates consisting of 
macrophages/microglia and T lymphocytes. Deposition of immunoglobulin and complement is not 
present in these lesions.  
In contrast to pattern I and II lesions, pattern III lesions show a diffuse spread into the normal-
appearing white matter and the myelin around the vessels is mostly intact. The characteristic 
features of this pattern are a preferential loss of the myelin-associated glycoprotein (MAG) 
compared to other myelin proteins (e.g. myelin oligodendrocyte glycoprotein (MOG) and the 
apoptosis of oligodendrocytes.  
The hallmark of pattern IV lesions is DNA fragmentation in oligodendrocytes in the absence of 
morphological features of apoptotic cell death. This pattern was only described in single autopsy 
cases and can thus be neglected.  
1.1.3. B cells in MS 
In the past years, the hypothesis of MS as a mainly T cell-mediated disease has been questioned 
and the role of B cells in the pathogenesis has been reevaluated (Franciotta et al., 2008). 
Activation of naïve B cells is triggered by antigen which they present in the context of the major 
histocompatibility complex-II (MHC-II) to CD4+ T cells.  
Full activation of B cells usually requires T cell help, namely the interaction of co-stimulatory 





can differentiate into antibody-secreting plasma cells and memory B cells. These responses are 
crucial for a proper humoral and cellular immune response to effectively eliminate pathogens. 
Furthermore, activated B cells produce various pro-inflammatory cytokines (e.g. IL-6, TNFα, IFNγ) 
that on one side are important for an inflammatory response against pathogens but on the other 
side could promote inflammation in autoimmune diseases leading to the exacerbation of the 
disease course (Krumbholz and Meinl, 2014). Besides pro-inflammatory cytokines, B cells also 
secrete regulatory cytokines (e.g. IL-10, IL-35) which can control the extent of inflammation and 
could therefore exert beneficial effects in autoimmune diseases like MS (Fillatreau et al., 2002). In 
conclusion, B cells can exert beneficial and detrimental effects by antigen presentation, (auto-) 
antibody production and cytokine secretion.  
The presence of oligoclonal bands (OCBs) in the CSF of MS patients was a first indication that 
B cells could contribute to the pathogenesis of the disease (Karcher et al., 1959; Lowenthal et al., 
1960). OCBs occur in more than 95% of patients with MS and originate from the intrathecal 
production of IgG by clonally expanded plasma cells which are observed in the CNS parenchyma 
(Obermeier et al., 2011; Owens et al., 2003). Plasma cells are found in the perivascular spaces 
within lesions of subacute and chronic MS patients and it is assumed that antibodies (e.g. IgG) are 
synthesized at these sites (Henderson et al., 2009; Prineas, 1979). Additionally to the CNS 
parenchyma, B cell infiltrates are also found in the meninges of MS patients. Although only minor 
numbers of B cells and plasma cells are observed in MS lesions compared to T cells and myeloid 
cells, Type II lesions (that display deposits of Igs and complement and thus suggest a role of the 
humoral immune system in lesion development) are the most common lesion type in MS (Barnett 
et al., 2009; Lassmann et al., 2007; Lucchinetti et al., 2000).  
While these first observations focused mainly on the pathogenic contribution of antibodies, 
emerging evidence suggests that the cellular function of B cells as highly effective and selective 
antigen-presenting cells (APC) may be equally important. An evidence for a pathogenic cellular 
function of B cells was the observation that memory B cells of RRMS patients are capable of 
inducing CD4+ T cell proliferation and secretion of IFNγ in the presence of myelin proteins (Harp et 
al., 2010). B cells bind antigen via their B cell receptor (BCR), afterwards the antigen is internalized, 
processed and finally presented on the surface in the context of the major histocompatibility 





like CD80, CD86 and CD40 for an optimal capability to activate T cells. The co-stimulatory 
molecules CD80 and CD86 are upregulated on peripheral B cells from MS patients when compared 
to healthy controls (Fraussen et al., 2014). These B cells are capable of inducing a myelin-specific, 
pro-inflammatory T cell response, emphasizing the important role of B cell-dependent antigen 
presentation and co-stimulation in MS pathogenesis. Additionally, B cells can contribute to a pro-
inflammatory response through the production of cytokines like Interleukin (IL)-6 and tumor 
necrosis factor alpha (TNF-α) (Meinl et al., 2006). It was demonstrated that B cells isolated from 
MS patients and afterwards stimulated in vitro showed a significant higher production of IL-6 
when compared to healthy controls (Barr et al., 2012). Furthermore, MS plaques show an up-
regulation of the B cell activation factor (BAFF) with an expression level comparable to lymphoid 
tissue (Krumbholz et al., 2005). BAFF serves as a crucial survival factor for B cells, especially for 
autoantigen binding B cells (Lesley et al., 2004). Therefore, an increased BAFF expression could 
promote the long-term-survival of plasma cells in the CNS. In contrast to these findings, it was 
shown that the frequency of regulatory B cells is decreased in the peripheral blood of MS patients 
compared to healthy controls (Knippenberg et al., 2011). B cells themselves can regulate immune 
responses through the production of IL-10 and IL-35 (Fillatreau et al., 2002; Shen et al., 2014). 
Besides, human regulatory B cells can control dendritic and macrophage cell functions, suppress 
proliferation of T cells and induce the generation of regulatory T cells (Krumbholz and Meinl, 
2014). Balancing the pro-inflammatory and regulatory functions of B cells, for example through 
influencing the BAFF expression level, could be an important therapeutic target for MS. 
The most conclusive evidence for a pathogenic contribution of B cells in MS pathogenesis were the 
beneficial effects of the B cell-depleting antibody rituximab and ocrelizumab (and other B cell-
depleting therapeutics in clinical development) in RRMS patients (Hauser et al., 2008a, 2017). 
1.1.4. Therapy of MS 
The treatment approaches in MS can be divided into disease-modifying therapies and the 
treatment of acute relapses. The choice for the initial disease-modifying MS medication depends 
on the disease activity and is also based on a benefit-risk evaluation. Today, more than ten 






The DMDs for patients with mild/moderate disease activity are the injectable drugs interferon-
beta (IFNβ) and glatiramer acetate (GA) as well as the recently developed orally active drugs 
dimethyl fumarate (DMF) and teriflunomide. These drugs are characterized by moderate 
immunomodulatory functions and a generally high safety profile. Teriflunomide should not be 
used for women who are pregnant or are planning a pregnancy within the next 2 years. Several 
clinical trials could show that IFNβ, GA, teriflunomide and DMF efficiently reduce the relapse rate, 
decrease the development of new MRI lesions and counteract Expanded Disability Status Scale 
(EDSS) worsening (Claussen and Korn, 2012; Fox et al., 2012; Gold et al., 2012; Kappos et al., 2007; 
McCormack and Scott, 2004; Mikol et al., 2008; Paty and Li, 1993). The effects of DMF are 
described in detail in section 12. 
For MS patients with a (highly) active disease course, monoclonal antibodies (mAbs) such as 
natalizumab and alemtuzumab or the oral agent fingolimod can be used as first choice of 
treatment. All three medications are characterized by a higher therapeutic efficacy than for 
example IFNβ. These drugs are highly effective in reducing the relapse rate as well as decreasing 
the accumulation of disability and MRI activity (Cohen et al., 2010; Coles et al., 2012; Polman et 
al., 2006). Although natalizumab was proven to be very effective, the development of progressive 
multifocal leukoencephalopathy (PML) in natalizumab-treated patients became a major safety 
issue (Langer-Gould and Steinman, 2006). Since the risk to develop PML is associated with the 
presence of antibodies against the JCV, patients should be tested for those antibodies before 
starting natalizumab treatment and while on therapy (Plavina et al., 2014). If these first line drugs 
fail to effectively control disease activity, daclizumab, mitoxantrone and ocrelizumab (expected to 
be approved in 2017) are considered as alternative treatment option. Daclizumab and ocrelizumab 
are mAbs which significantly lower the relapse rate of MS patients (Gold et al., 2013; Kappos et al., 
2011). Mitoxantrone is an immunosuppressive drug which was approved in 2000 for the therapy 
of worsening RRMS and is known to significantly reduce the relapse rate and worsening of 
symptoms (Vollmer et al., 2010).  
The standard medication for an acute relapse is the daily intravenous administration of high dose 
corticosteroids (e.g. 1g/day methylprednisolone) for 3-5 days (Sellebjerg et al., 2005). Should the 





second therapy option, immunoadsorption or plasma exchange are utilized for patients with no or 
incomplete recovery after steroid treatment (Heigl et al., 2013; Trebst et al., 2009).  
Besides the primary treatment objective to reduce relapse rate and to retard disease progression, 
the symptomatic MS therapy targets known signs and comorbidities of MS. Therapeutic 
approaches such as physical therapy, application of muscle relaxants and medications against 
fatigue, depression, bowel/bladder control problems or visual dysfunctions are important to 
improve the quality of life for patients (de Sa et al., 2011). 
Most of the disease modifying drugs described above have also been tested for the therapy of 
progressive MS (PMS) with largely disappointing results (Ontaneda et al., 2016). It was shown that 
mitoxantrone was effective in patients with SPMS, but it rather reduced the relapse rate and did 
not affect the continuous disease progression (Ontaneda and Fox, 2015; Stüve et al., 2004). The 
limited success of these immunomodulatory and immunosuppressive drugs suggested that 
neuroprotective and repair-promoting approaches might be more effective for the therapy of 
PMS. However, the incomplete understanding of pathological processes contributing to the 
progression of disease complicates the development of such approaches. Hence, a broad range of 
treatments are currently under investigation.  One example is the clinical trial MS-SMART, which 
currently investigates three neuroprotective agents (amiloride, riluzole, fluoxetine) for the therapy 
of SPMS patients.  
1.2.  Animal models of MS  
Based on the restricted access to ex vivo specimens and the heterogeneity of MS, animal models 
are essential for a better understanding of the disease pathogenesis and for developing new 
therapeutic approaches. Several animal models of MS, like the cuprizone and EAE model, have 
been established, reproducing specific features of the disease. 
1.2.1. The cuprizone model 
The cuprizone model is a toxic demyelination model, which was developed to investigate 
demyelination and remyelination. The hallmark of this model is that the blood-brain-barrier (BBB) 
remains intact, which allows the analysis of de- and remyelination without major influences of the 
peripheral immune system (Bakker and Ludwin, 1987; McMahon et al., 2002). Cuprizone (bis-





mice leads to apoptosis of oligodendrocytes and the spontaneous demyelination of the corpus 
callosum (CC) (Bénardais et al., 2013; Matsushima and Morell, 2001a). The most common mouse 
strain used for the cuprizone model is the C57BL/6 strain. C57BL/6 mice fed with 0.2 – 0.25 % 
cuprizone for six weeks suffer from an almost complete demyelination of the CC (Hiremath et al., 
1998). Besides weight loss and a slightly decreased activity, no major clinical signs (e.g. paralysis) 
can be observed under 0.2 – 0.25% cuprizone exposure (Praet et al., 2014). Several studies 
showed that cuprizone also leads to demyelination in several other brain regions such as the 
cerebellum, the hippocampus, the caudate-putamen and cortex (Groebe et al., 2009; Gudi et al., 
2009; Hoffmann et al., 2008; Koutsoudaki et al., 2009; Norkute et al., 2009; Skripuletz et al., 2010). 
The exact mechanism of cuprizone-induced demyelination and apoptosis of oligodendrocytes is 
not completely understood. It is assumed that the cuprizone-mediated inhibition of mitochondrial 
enzymes leads to oligodendrocyte apoptosis and initiation of demyelination (Bénardais et al., 
2013; Matsushima and Morell, 2001a; Ransohoff, 2012; Venturini, 1973). Oligodendroglial cell 
death starts early after initiation of cuprizone diet, weeks before demyelination is detectable 
(Hesse et al., 2010a). In the early phase, dying oligodendrocytes express activated caspase 3, 
which decreases in later stages suggesting a switch to a caspase 3-independent cell death 
mechanism. The early loss of oligodendrocytes leads to an enhanced recruitment of 
microglia/macrophages which is followed by an extensive astrogliosis (Hiremath et al., 1998). 
Microglia accumulation reaches its maximum with the peak of demyelination after 4-5 weeks of 
cuprizone exposure (Mason et al., 2001). Spontaneous remyelination occurs either upon cuprizone 
withdrawal or after 5-6 weeks of ongoing cuprizone diet. After cuprizone removal, the majority of 
axons is remyelinated within 2 weeks (Lindner et al., 2008a).    
1.2.2. Experimental autoimmune encephalomyelitis  
EAE is the most common model of MS and was first described in 1933 (Rivers et al., 1933). The 
model is mainly used to study the immune cell-mediated inflammation and demyelination of the 
CNS. EAE can be induced by active immunization with distinct myelin components emulsified in 
complete Freund’s adjuvant (CFA) or by adoptive transfer of myelin-specific T cells (Stromnes and 
Goverman, 2006a, 2006b).  
Several murine EAE models were established in the past years including PLP139-151 peptide-induced 





C57/BL6 mice and active immunization with CNS tissue homogenates or MOG that induces a 
relapsing-remitting disease in Biozzi ABH mice (Amor et al., 1994; Ando et al., 1989; Mendel et al., 
1995; Tuohy et al., 1992). First clinical signs of EAE can be observed 9-12 days after immunization, 
depending on the species and the specific disease-inducing agents (Gold et al., 2006). The main 
clinical characteristic of EAE is an ascending paralysis, gradually affecting the hind limbs, 
abdominal muscles and fore limbs. 
EAE is mediated by complex interactions of the adaptive and the innate immune system. The most 
common active immunization model is the MOG35-55 peptide EAE model that leads to a relapsing-
remitting (SJL, Biozzi) or a chronic-progressive (C57BL/6) disease course.  The immunization 
together with CFA leads to a primarily CD4+ T cell-mediated disease (Fletcher et al., 2010; 
Kurschus, 2015). The MOG35-55 peptide-containing CFA is recognized by antigen-presenting cells 
(APCs), such as dendritic cells, macrophages and B cells, which present the antigen in a complex 
with MHC-II molecules on their surface leading to an activation of peripheral encephalitogenic T 
cells (Slavin et al., 2001). These autoreactive T cells migrate into the CNS mediating a subsequent 
breakdown of the BBB (Furtado et al., 2008; O’Connor et al., 2008). Inside the CNS, T cells become 
reactivated by local and infiltrating APCs which present myelin fragments in association with 
MHC-II leading to further inflammatory processes and subsequently to demyelination and axonal 
injury (Fletcher et al., 2010; Steinman and Zamvil, 2005). The disease worsening caused by 
depletion of B cells led to the assumption that this model can be considered as a rather “B cell-
independent” EAE (Weber et al., 2010). An EAE model which generates antigen-activated B cells is 
achieved by immunization with recombinant MOG protein (recombinant (r) MOG1-117). After mice 
are immunized with MOG35-55 peptide, autoreactive CD4+ T cells become directly activated 
because the peptide is bound by MHC-II on APCs without processing (Constant et al., 1995; Slavin 
et al., 2001). In contrast, after immunization with rMOG1-117 the native MOG needs to be 
internalized and processed by APCs to present the encephalitogenic peptide to autoreactive 
CD4+ T cells (Slavin et al., 2001). This leads to the generation of pathogenic B cells, which recognize 
the MOG-protein via their B cell receptor (BCR). These B cells can, subsequently, efficiently 
activate CD4+ T cells and develop into antibody-secreting plasma cells (Marta et al., 2005). 
Although these EAE models represent several histopathological and immunological features of MS, 





more suitable to investigate the initiation of the disease are spontaneous EAE models. 
Opticospinal encephalomyelitis (OSE) mice spontaneously develop lesions restricted to the optic 
nerve and spinal cord (Krishnamoorthy et al., 2006). These mice are double-transgenic animals on 
a C57BL/6 background, which have transgenic T cells specific for myelin oligodendrocyte 
glycoprotein peptide 35-55 (MOG 35-55) and transgenic B cells recognizing MOG antigen 
(Litzenburger et al., 1998). Approximately 50% of OSE mice develop spontaneous EAE. Another 
spontaneous EAE model is the RR mouse model (SJL/J background) which represents the first 
spontaneous animal model for the relapsing-remitting form of MS (Pöllinger et al., 2009). These 
single-transgenic mice carry T cells with a T cell receptor (TCR) specific for the MOG91-106 peptide 
presented by MHC-II. Within one year 90% of the animals develop a relapsing-remitting course of 
EAE with lesions distributed throughout the CNS. 
1.3. The oral agent dimethyl fumarate (DMF) 
The fumaric acid ester DMF (Tecfidera®) is approved for the therapy of RRMS in Germany since 
February 2014. Previously DMF had been approved as a compound of the anti-psoriatic drug 
Fumaderm® since 1994, based on successful clinical studies (Altmeyer et al., 1994; Mrowietz et al., 
1998; Nieboer et al., 1990). DMF has several immunomodulatory functions, but the mechanism of 
action is not completely understood. In the circulation, DMF is rapidly hydrolyzed to its metabolite 
monomethyl fumarate (MMF), which is supposed to be the active form in the body (Nibbering et 
al., 1993). However, in vitro and in vivo studies could show that both DMF and MMF have 
immunomodulatory effects (de Jong et al., 1996; Ockenfels et al., 1998; Treumer et al., 2003). 
1.3.1. Clinical MS trials of DMF 
Several clinical studies assessed the therapeutic effects, safety and tolerability of DMF in RRMS 
patients. The initial study was performed with Fumaderm® which is composed of ethylhydrogen 
fumarate-Ca salt, ethylhydrogen fumarate-Mg salt, ethylhydrogen fumarate-Zn salt and dimethyl 
fumarate. This pilot study showed that treatment of RRMS patients with fumaric acid esters (FAE) 
could significantly reduce the number and volume of gadolinium-enhanced (Gd+) lesions and 
modulate T cell-mediated cytokine production (Schimrigk et al., 2006). Based on these preliminary 
findings, an oral formulation of dimethyl fumarate, named BG-12, was tested in a phase II study in 
patients with RRMS (Kappos et al., 2008). Treatment with 240 mg DMF three times daily 





compared with placebo treated patients. Furthermore, the number of new or enlarging T2-
hyperintense and new T1-hypointense lesions was reduced by DMF. Two randomized, double-
blind phase III studies, the DEFINE (Gold et al., 2012) and the CONFIRM study (Fox et al., 2012), 
were performed.  
The DEFINE study demonstrated that DMF significantly reduces the number of relapses in MS 
patients (relapse rate: 27% with DMF twice daily and 26% with DMF thrice daily vs. 46% placebo) 
as well as the number of Gd+ and new or enlarging T2-hyperintense lesions. The risk of disability 
progression was reduced by 38% and 34% with DMF treatment twice or thrice per day, 
respectively. In the CONFIRM study, the active agent GA was included as a reference comparator. 
The results regarding the efficacy and safety of DMF compared to placebo were fairly similar to 
the results of the DEFINE study. The comparison of DMF versus GA showed significant differences 
in favour of DMF in the annualized relapse rate (thrice-daily DMF), new or enlarging T2-
hyperintense lesions (both DMF doses), and new T1-hypointense lesions (thrice-daily DMF). 
Adverse effects include gastrointestinal symptoms like abdominal pain and diarrhea, flushing and 
decreased lymphocyte counts. To minimize the risk of severe lymphopenia it is recommended to 
monitor complete blood count and absolute lymphocyte counts before the initiation and during 
DMF treatment. To date, 5 cases of PML have been reported with the use of fumaric acid esters in 
patients with psoriasis and 4 cases of PML in patients with MS treated with DMF (Rosenkranz et 
al., 2015; Williamson and Berger, 2015). 
The FDA approved DMF (Tecfidera®) in 2013 and the European Commission in 2014 as first-line 
oral treatment for patients with RRMS. The starting dose of Tecfidera® is 120 mg twice a day 
orally, after seven days the dose should be increased to 240 mg twice daily. 
1.3.2. Experimental DMF studies in vivo 
The effects of DMF were investigated in different animal models. In MOG35-55 peptide induced 
EAE, preventive DMF treatment of mice with 15 mg/kg twice daily could significantly ameliorate 
the clinical course compared to controls (Chen et al., 2014; Schilling et al., 2006; Schulze-Topphoff 
et al., 2016). The infiltration of macrophages into the spinal cord was significantly reduced in the 
early phase of EAE. Therapeutic application of DMF, started after EAE onset, could also attenuate 





Histological analysis revealed that DMF leads to a significantly better preservation of myelin and 
axons in inflamed lesions as well as to a reduced astrogliosis.  
A quantification of neuronal cells in spinal cord and cerebellum showed significantly higher 
numbers of neurons in DMF-treated mice compared to controls. It was shown that DMF can 
induce the nuclear factor erythroid 2-related factor (Nrf2) which leads to an increased activation 
of antioxidant response pathways (Thiessen et al., 2010). In vivo application of DMF led to an 
increased induction of Nrf2 target genes such as NADP(H) quinolone oxidoreductase-1 (NQO-1) in 
liver and cerebellum of MOG-peptide immunized rats (Linker et al., 2011). Furthermore, 
histological evaluation of DMF-treated EAE animals revealed an increased expression of Nrf2 in 
neurons and glial cells in the brain and spinal cord, suggesting that the observed neuroprotective 
effects of DMF are Nrf2-dependent. The study of Linker et al. demonstrated that DMF treatment 
could not ameliorate the EAE course of Nrf2 k.o. mice and thereby supported the hypothesis that 
DMF effects are mostly Nrf2-dependent. Nevertheless, a recent study showed that DMF treatment 
also ameliorated EAE of Nrf2 k.o. mice to the same extent as in WT mice, indicating that DMF may 
as well act via alternative pathways (Schulze-Topphoff et al., 2016). A further study suggested that 
the hydroxycarboxylic acid receptor 2 (HCA2) could contribute to the protective effects of DMF in 
EAE, since DMF could not ameliorate the EAE course in HCA2k.o. mice (Chen et al., 2014). MMF 
was shown to be a potent agonist of the HCA2 receptor, which is expressed on immune cells, 
especially neutrophils (Lukasova et al., 2011). Chen et al. assumed that DMF treatment could exert 
secondary immunomodulatory functions by impairing the recruitment of neutrophils.  
DMF and MMF were also analyzed in the toxic cuprizone model, a model to investigate direct CNS 
effects of treatments independent of the peripheral immune system. MMF and DMF treatment 
revealed only minor effects on the demyelination of the CC (Moharregh-Khiabani et al., 2010). 
Furthermore, neither MMF nor DMF induced significant changes concerning the number of 
mature oligodendrocytes or OPCs.  The cuprizone-induced microgliosis, astrogliosis and acute 
axonal damage were also not majorly changed by MMF or DMF treatment. MMF and DMF could 
slightly accelerate the remyelination in the CC.  
1.3.3. DMF effects on CNS resident cells in vitro  
DMF treatment in EAE showed that it exerts beneficial effects on different CNS cell populations. 





astrocytes (Linker et al., 2011; Reick et al., 2014).  The effects of DMF were also investigated on 
microglia, endothelial cells, astrocytes, neurons and oligodendrocytes in vitro. Both, MMF and 
DMF application leads to an increased activation of antioxidant response pathways via induction 
of Nrf2 (Linker et al., 2011; Thiessen et al., 2010). DMF treatment of neurons and astrocytes in 
vitro resulted in an upregulation of a Nrf2-dependent antioxidant response and could significantly 
increase the cell viability after toxic oxidative challenge (Scannevin et al., 2012a). Low 
concentrations of DMF (10 µM) increase the synthesis and recycling of glutathione, an important 
intracellular antioxidant, in neuronal cells (Albrecht et al., 2012). Enhanced levels of antioxidant 
molecules (e.g. glutathione) are produced by oligodendrocytes when these were treated in vitro 
with DMF leading to an increased protection against oxidative stress (Albrecht et al., 2012). 
Furthermore, DMF decreases the synthesis of pro-inflammatory cytokines like TNF-α, IL-1β and IL-
6 in activated astrocytes and microglia in vitro (Wilms et al., 2010). DMF also profoundly decreases 
the TNFα-induced expression of adhesion molecules E-selectin, ICAM-1 and VCAM-1 on 
endothelial cells and reduces lymphocyte rolling, firm adhesion and diapedesis in vitro (Wallbrecht 
et al., 2011).  
1.3.4. DMF effects on immune cells in vitro and in vivo 
Besides the induction of the Nrf2-dependent antioxidant response element (ARE) pathway, DMF 
and MMF were able to inhibit the translocation and DNA-binding of nuclear factor κB (NF-κB), 
resulting downstream in altered cell maturation, reduced inflammatory cytokine production and 
function of antigen-presenting cells (Ghoreschi et al., 2011; Gillard et al., 2015; Litjens et al., 2006; 
Loewe et al., 2001). Several studies could reveal that ARE induction can inhibit the NF-κB signaling 
pathway and indirectly regulate inflammatory chemokine and cytokine production (Wakabayashi 
et al., 2010).  
Application of DMF or MMF in vitro reduces the CCL-2 induced chemotaxis of human monocytes 
that is needed for CNS infiltration (Cross et al., 2011). In addition, in vitro experiments with 
cultured mononuclear blood cells revealed that DMF has anti-inflammatory functions by inducing 
T-helper cell type 2 (Th2) immune responses (de Jong et al., 1996). The DMF metabolite MMF 
increases the production of IL-5 and IL-4, which are driving Th2 cell development. It was later 
shown, that this effect could be linked to a direct effect of MMF on dendritic cells (DCs) (Litjens et 





responses, such as IFNγ secretion, by modulating the polarization of DCs. In humans and mice, 
DMF treatment stimulates the development of type II DCs that produce IL-10 and induce IL-4-
producing Th2 cells in vitro  and in vivo (Ghoreschi et al., 2011). Furthermore, in vivo DMF 
treatment of MS patients leads to an alteration of circulating T helper cell subsets by decreasing 
the frequencies of Th1 cells and increasing the Th2 cell proportions (Gross et al., 2015). CD4+ and 
CD8+ memory T cells are also decreased with the use of DMF whereas the regulatory T cell 
population remains unaltered. Recent studies revealed that DMF influences B cell subsets of 
patients with RRMS, resulting in an increased number of B cells with regulatory functions (Lundy et 
al., 2016).  
1.4. Aim of the study 
The oral agent dimethyl fumarate (DMF) shows efficacy in the therapy of RRMS. It is assumed that 
DMF mainly acts via modulating the peripheral immune system and especially by reducing the pro-
inflammatory properties of T cells (Gross et al., 2015; Mrowietz et al., 1998). Additionally, DMF 
treatment is suggested to exert neuroprotective effects through the activation of the transcription 
factor Nrf2 which in turn mediates the activation of ARE. Whether DMF can exert direct 
neuroprotective effects independent of the peripheral immune system is controversially 
discussed. Furthermore, it is still unknown if DMF has any direct immunomodulatory effects on 
B cells whose role in MS pathogenesis became increasingly important in the recent years.  
In the first part of my thesis it was investigated if DMF exerts any CNS intrinsic effects independent 
of peripheral inflammation. DMF effects were analyzed on: 
A1. Neurodegeneration including apoptosis of oligodendrocytes, demyelination and axonal damage as 
well as 
A2. Neuroregeneration investigating remyelination, oligodendrocyte preservation and maturation. 
In the second part of my thesis it was studied if DMF treatment is effective in a B cell-mediated 
EAE model. DMF effects were investigated on: 
B1. Clinical course and histopathology of B cell-mediated EAE. 
B2. Activation, functional properties and subtypes of B cells and T cells during the acute phase of EAE. 
  




 Material and Methods 
2.1. Material 
2.1.1. Reagents 
Table 2: Reagents 
REAGENT SOURCE OF SUPPLY 
Acetic Acid Merck Millipore, Germany 
Agarose  Starlab GmbH, Germany  
BD FACS Clean™  BD Biosciences, USA  
BD FACS Flow™  BD Biosciences, USA  
BD FACS Rinse™  BD Biosciences, USA  
BD FACS™ Lysing Solution, 10x  BD Biosciences, USA  
BD Pharm Lyse™, 10x  BD Biosciences, , USA  
Boric Acid  Merck Millipore, Germany  
Crystal Violet  Sigma Aldrich, USA  
Cytofix/Cytoperm™  BD Biosciences, , USA  
Cytofix™  BD Biosciences, USA  
Chloral Hydrate  Merck Millipore, Germany  
Citric Acid  Merck Millipore, Germany  
DAB (3,3’-Diaminobenzidine)  Sigma-Aldrich Chemie GmbH, Germany  
DAPI (4’,6-Diamidino-2-Phenylindole)  Sigma-Aldrich Chemie GmbH, Germany  
DDSA (2-Dodecenylsuccinic Acid Anhydride)  Serva Electrophoresis GmbH, Germany  
DEPEX VWR International, Germany  
DMF (Dimethyl Fumarate) Biogen Idec, USA 
DMSO (Dimethyl Sulfoxide)  Sigma Aldrich, USA  
EDTA (Ethylenediamine Tetraacetic Acid 
Disodiumsalt Dihydrate)  
Carl Roth, Germany  




Ethanol, 100%  Merck Millipore, Germany  
Ethidium Bromide  Sigma Aldrich, USA  
Eosin G  Merck Millipore, Germany  
FCS (Fetal Calf Serum)  Sigma Aldrich, USA  
Foxp3 Fixation/Permeabilization 
Concentrate  
Ebioscience, USA  
Foxp3 Fixation/Permeabilization Diluent  Ebioscience, USA  
Foxp3 Permeabilization Buffer, 10x  Ebioscience, USA  
Generuler™, 100 Base Pairs (bp) DNA 
Ladder Plus  
ThermoFisher Scientific, USA  
Go-Taq® DNA Polymerase Buffer, 5x  Promega, USA  
HCl (Hydrochloric Acid)  Merck Millipore, Germany  
H2O2 (Hydroxic Peroxide), 30%  Merck Millipore, Germany  
HPMC (Hydroxypropylmethylcellulose) Biogen Idec, , USA 
Ionomycin  Sigma Aldrich, USA 
Isopropyl Alcohol  Merck Millipore, Germany  
L-Glutamine, 200 Mm  Sigma Aldrich, USA  
LPS (Lipopolysaccharide)  Sigma Aldrich, USA  
Mayer’s Hemalum  Merck Millipore, Germany  
NaCl (Sodium Chloride), 0.9% Solution, 
Sterile  
B. Braun Melsungen AG, Germany  
NaCO3 (sodium carbonate) Merck Millipore, Germany  
NaHCO3 (sodium hydrogen carbonat) Merck Millipore, Germany  
NaF (sodium fluoride) Merck Millipore, Germany 
Paraffin Oil  Carl Roth, Germany  
PBS (Phosphate Buffered Saline), 10x  Biochrom AG, Germany  
PBS (Phosphate Buffered Salt Solution), 
Sterile  
Sigma Aldrich, USA  




Penicillin, 10,000 Units   Sigma Aldrich, USA 
Perm/Wash™ Buffer, 10x  BD Biosciences, USA  
PFA (Paraformaldehyde), Powder  Merck Millipore, Germany  
PMA (Phorbol 12-Myristate 13-Acetate)  Sigma Aldrich, USA 
RPMI-1640 (Roswell Park Memorial 
Institute-1640)  
Sigma Aldrich, USA 
Sodium Pyruvate, 100 mM  Sigma Aldrich, USA 
TMB (3,3’,5,5’-Tetramethylbenzidine) 
Substrate Solution  
Ebioscience, USA  
Tris (Tris(Hydroxymethyl)Aminomethane)  Carl Roth, Germany  
Trypan Blue  Sigma Aldrich, USA 
Tween Merck Millipore, Germany 
β-Mercaptoethanol  Sigma Aldrich, USA 
 
2.1.2. Solutions, buffers and cell culture media 
Table 3: Solutions, buffers and cell culture media 
SOLUTION COMPOSITION 
Blocking Buffer for Immunohistochemistry  PBS  
10% FCS 




Paraffin oil  
15% mannide monooleate  
6.7 mg/ml Mycobacterium tuberculosis 
H37RA 
Chloral Hydrate, 14%  distilled water  
14% chloral hydrate  
  




Citric Acid Buffer, 10 Mm  2.1 g citric acid  
1 l distilled water  
NaOH, adjust to pH 6  
Coating buffer 8.4 g NaHCO3 
3.5 g NaCO3 
1 l distilled water 
Stir filter, adjust to pH 9.5 
Cryo medium 60% RPMIcomplete 
20% DMSO 
20% FCS 
3,3’-Diaminobenzidine Tetrachloride (Dab) 
Working Solution  
PBS  
0.5 mg/ml DAB  
add 20 μl 30% hydrogen peroxidase per 
50 ml DAB solution before use  
ELISA wash buffer 200 ml 10x PBS 
1 ml Tween 
1.8 l distilled water 
ELISA stop solution 1 N H2 SO4 solution 
1% Eosin  70% isopropyl alcohol  
1% eosin G 
stir filter, before use add 0,5% acetic 
acid  




FACS (Fluorescence-Activated Cell Sorting) 
Buffer  
PBS, sterile  
2% FCS  
1% HCl  1% HCl absolute  
70% ethanol  
MACS (Magnetic-Activated Cell Sorting) Buffer  PBS, sterile  
0.5% FCS  
2 mM EDTA  
pH 7.2  
Neutralization buffer 40 mM Tris 
250 ml distilled water 
10x PBS 95.5 g PBS 
1 l distilled water 
RD1 buffer (ELISA block buffer) 200 ml 10x PBS 
20 g BSA 
1.8 l distilled water 
RPMIcomplete  RPMI-1640  
10% FCS  
1 mM sodium pyruvate  
50 μM β-Mercaptoethanol  
100 units penicillin  
2 mM L-glutamine  
TAE (Tris, acetic acid, EDTA) buffer  40 mM Tris 
20 mM acetic acid  
1 mM EDTA 
1 l distilled water (adjusted to pH 8) 
Tail lysis buffer 25 mM NaOH 
2 mM EDTA 
250 ml distilled water 




2.1.3. Antibodies, enzymes and proteins 
Table 4: Proteins, enzymes and inhibitors 
PROTEINS, ENZYMES, INHIBITORS SOURCE OF SUPPLY 
BSA (bovine serum albumin)  SERVA Electrophoresis GmbH, Germany  
Recombinant mouse MOG-protein1-117  Monash University, Australia  
PTX (pertussis toxin)  List biological laboratories, USA  
DNase I  Roche, Basel, Switzerland  
Dreamtaq green PCR master mix (2x)  Thermo Fisher Scientific, USA 
Proteinase K  Sigma Aldrich, USA  
Trypsin, 0.05%  Gibco/Invitrogen, USA  
Golgistop™  BD Biosciences, USA  
 
Table 5: Monoclonal antibodies for flow cytometry 
SPECIFICITY  FLUOROCHROME  CLONE  DILUTION  SOURCE OF SUPPLY  
B220 FITC RA3-6B2 1:100 BioLegend 
B220 PE-Cy7 RA3-6B2 1:100 BD Biosciences 
CD1D Pacific Blue 1B1 1:100 BioLegend 
CD4 BV510 GK1.5 1:100 BioLegend 
CD4 PE RM4-5 1:100 BioLegend 
CD5 PerCP-Cy5.5 53-7.3 1:100 BioLegend 
CD8a FITC 53-6.7 1:100 BioLegend 
CD19 APC-Cy7 6D5 1:100 BioLegend 
CD19 FITC HIB19 1:100 BD  
CD23 APC B3B4 1:100 BioLegend 




CD25 APC PC61 1:100 BD Biosciences 
CD27 FITC LG.3A10 1:100 BioLegend 
CD37 PE Duno85 1:100 BioLegend 
CD40 APC 3/23 1:100 BD 
CD40 PE 5C3 1:100 BioLegend 
CD38 Pacific  
Blue 
90 1:100 BioLegend 
CD69 PerCP-Cy5.5 H1.2F3 1:100 BD Biosciences 
CD80 APC 16-10A1 1:100 BD Biosciences 
CD80 PerCP-Cy5.5 2D10 1:100 BioLegend 
CD86 PE GL1 1:100 BD Biosciences 
CD95 (FAs) PE Jo2 1:100 BD Biosciences 
CD138 BV-605 281-2 1:100 BioLegend 
Foxp3 PE FJK-16s 1:100 e-bioscience 
GL-7 FITC GL7 1:100 BioLegend 
IFNΓ APC XMG1.2 1:100 BioLegend 
IgM FITC RMM-1 1:100 BioLegend 
IgD PE 11-26c.2a 1:100 BD Biosciences 
IL-17 PE TC11-18H10 1:100 BD Biosciences 
MHC-II Pacific Blue AF6-120.1 1:100 BioLegend 




MHC-II PE AF6-120.1 1:100 BD Biosciences 
 
Table 6: Monoclonal antibodies for antigen-independent activation of T cells in vitro 
SPECIFITY CLONE SOURCE OF SUPPLY 
LEAF™ purified anti-mouse CD3  145-2C11 BioLegend 
LEAF™ purified anti-mouse CD28 37.51 BioLegend 
 
Table 7: Primary antibodies for immunhistochemical staining 
SPECIFICITY  SPECIES/CLONE ANTIGEN 
RETRIEVAL/FIXATION 
DILUTION SOURCE OF 
SUPPLY 
APP mouse/MAB348 microwave, citric acid 
buffer 
1:2000 Merck Millipore 
B220 rat microwave, citric acid 
buffer 
1:200 BD Pharmingen 
Casp3 rabbit/C92-605 Microwave, Tris-EDTA 1:150 BD Biosciences  
CD3  rat/ CD3-12  microwave, citric acid 
buffer  
1:200  Biorad 
CNPase Mouse/SMI-91R microwave, citric acid 
buffer 
1:200 Covance 
GFAP mouse microwave, citric acid 
buffer 
1:300 Synaptic Systems 
 
GFAP rabbit  none 1:1000  DAKO  
MAC3 Rat/ M3/84 microwave, citric acid 
buffer 
1:200 BD Pharmingen 
MBP rabbit/62301 none 1:1000 DAKO 
NogoA rabbit microwave, Tris-EDTA 1:50 Santa Cruz 




Olig2 rabbit microwave, Tris-EDTA 1:300 IBL 




Table 8: Secondary antibodies for immunohistochemical staining 
SECONDARY ANTIBODY  DILUTION  MANUFACTURER  
Anti-mouse IgG, biotinylated  1:200 GE Healthcare Europe GmbH, Germany  
Anti-rabbit IgG, biotinylated  1:200 GE Healthcare Europe GmbH, Germany  
Anti-rat IgG, biotinylated  1:200 GE Healthcare Europe GmbH, Germany  
 
Table 9: Applied Kits 
KIT SOURCE OF SUPPLY 
CD4+ T cell isolation kit II, mouse  Miltenyi Biotec, Germany  
Cell lineage panel kit, mouse Miltenyi Biotec, Germany  
Dylight 405 Antibody labeling Kit Thermo Fisher Scientific, USA 
   
2.1.4. Oligonucleotide primers 
Table 10: Primers 
NAME SEQUENCE SOURCE OF SUPPLY 
Ja18-2D2 5’-CCC GGG CAA GGC TCA GCC 
ATG CTC CTG-3’ 
Eurofins Scientific, 
Germany 
Va3-2-2D2-M 5’-GCG GCC GCA ATT CCC AGA 








2.1.5. Consumables  
Table 11: Consumables 
REAGENT SOURCE OF SUPPLY 
Bottle Top Filter, 0.2 µm  Sarstedt, Germany  
Cell Culture Plates, Flat Bottom (6 Well, 24 
Well, 96 Well)  
Greiner bio-one, Austria  
Cell Strainer (70 µm)  Greiner bio-one, Austria 
FACS Tube, 5 ml  Sarstedt, Germany 
LS Columns  Miltenyi Biotec, Germany  
Needles  BD Biosciences, USA  
Nunc™ Maxisorp® 96 Well ELISA Plate  Thermo Scientific, USA  
96 Well Plate Round Sarstedt, Germany 
Pre-Separation Filters, 30 µm  Miltenyi Biotec, Germany  
Syringes  BD Biosciences, USA  
Serum Microtubes Sarstedt, Germany 
Tubes (50 ml, 15 ml, 10 ml, 2 ml, 1,5 ml, 
 0.2 ml)  
Sarstedt, Germany  
 
  




2.1.6. Technical devices 
Table 12: Technical devices 
DEVICE SOURCE OF SUPPLY 
Bx51 Olympus light microscope equipped 
with DP71 digital and XM10 monochrome 
camera  
Olympus, Germany  
Centrifuge 5415 R  Eppendorf, Germany  
Centrifuge 5810 R  Eppendorf, Germany  
FACS LSR II BD Biosciences, USA  
GentleMACS™ Dissociator  Miltenyi Biotec, Germany  
Cell Incubator BBD6220 Thermo Scientific, USA 
IMARK™ Microplate Reader  Bio-Rad, Germany  
Microscope Olympus 
Microtome  Leica, Germany  
Microwave  Bosch, Germany  
Neubauer Chamber  Superior Marienfeld , Germany  
QuadroMACS™ Separator  Miltenyi Biotec, Germany  
T3 Thermocycler  Biometra, Germany  
TP 1020 (Tissue Processor)  Leica, Germany  
 
2.1.7. Software 
Table 13: Software 
SOFTWARE APPLICATION SOURCE OF SUPPLY 
BD biosciences FACSDiva software 
6.1.2  
Data acquisition flow 
cytometry  
BD Biosciences, USA  
FlowJo 10.1  Data analysis flow 
cytometry  
Tree Star Inc., USA  




GraphpadPrism 6  Statistical analysis  
Graphs  
GraphPad software Inc., USA  
ImageJ 1.47d  Data analysis histology  National Institutes of Health, 
USA  
PSremote 1.6.5  Gel documentation  Breeze systems limited, UK  
 
2.2. Patients 
Blood samples were obtained from non-treated and DMF-treated MS patients. MS patients 
receiving DMF were treated for at least six months.  
Table 14: Clinical characteristics of MS patients 
 Non-treated DMF-treated 
Age (years) 36 ± 10  36 ± 14 
Sex 4 female, 2 male 5 female, 1 male 
Disease duration (years) 7 ± 6 5 ± 5 
Therapy duration (month) - 6.5 ± 1 
EDSS 1.3 ± 0.4 0.8 ± 1.0 
 
  





C57Bl/6 mice  
8-12 week old female C57BL/6J mice were obtained from Charles River laboratories, Germany. 
Each experimental group contained 5-8 mice and each experiment was performed at least twice. 
All experiments were approved by the Lower Saxony authorities for animal experimentation. 
2D2 mice  
2D2 animals were generated and characterized by Bettelli and colleagues in 2003. 90-95% of the 
CD4+ T cells in 2D2 mice express the MOG35-55-specific T cell receptor Vα3.2/ Vβ11 (Bettelli et al., 
2003). 2D2 CD4+ T cells were used as reporter cells in several proliferation assays.  
Nrf2 k.o. mice 
A homozygous Nrf2 k.o. breeding pair was obtained from Jackson laboratory. Nrf2 k.o. animals 
were generated in 1996 by Chan and colleagues (Chan et al., 1996). In Nrf2 k.o. mice the genetic 
function of the transcription factor Nrf2 is abolished. 9-10 week old Nrf2 k.o. mice were cuprizone 
fed and used for further experiments.  
Breeding 
All transgenic mice were bred in the central animal facility of the University Medical Center 
Goettingen. 
Housing 
The mice were held under conventionally and specific pathogen free (SPF) conditions, they had 
access to food and water ad libitum and a 12h/12h light/dark cycle. Mice were allowed to adapt to 
the new environment for seven days before each experiment.   
2.4. Methods 
2.4.1. Genotyping 
For the genotyping of 2D2 mice, tissue was obtained via a tail biopsy. After DNA extraction, 
transgenes were amplified with specific primers and separated by agarose gel electrophoresis as 
described below. All genotyping was performed by Ms. Katja Grondey, Mr. Jan Einar Albin and Mr. 
Julian Koch (Department of Neuropathology, University Medical Center Germany). 





DNA was isolated from tail biopsies of 2D2 mice. The tissue was digested in 100 µl lysis buffer at 
99°C for 30 min. Afterwards 100 µl neutralization buffer was added. 
PCR reaction 
Each reaction sample contained 1 µl genomic DNA, 10 µl Dream Taq® PCR Mix 2x, 1 µl of each 
primer and 7 µl water (nuclease free).  
Primer 1: 5’-CCC GGG CAA GGC TCA GCC ATG CTC CTG-3’ 
Primer 2: 5’-GCG GCC GCA ATT CCC AGA GAC ATC CCT CC-3’ 
PCR conditions  
• Initial denaturation: 94°C, 2 min 
• 35 cycles: Denaturation:  94°C, 1 min 
Annealing:  58°C, 1 min 
Extension:  72°C, 1 min 
• Final extension:  72°C, 10 min 
Agarose gel electrophoresis 
For the analysis of PCR products, 5 µl of the sample were loaded on an agarose gel (2%(w/v) in TAE 
buffer) containing 3 µl ethidium bromide/GelRed. Electrophoresis was performed in a Sub-Cell GT 
Agarose Gel Electrophoresis System at 120V for 45 min. Evaluation of PCR products was done by 
visualization and documentation by UV-light in a gel-documentation device. 
2.4.2. Cuprizone treatment 
Mice received cuprizone at a 0.25% dosage ad libitum. Therefore 2.5 g cuprizone were mixed with 
1000 g ground mouse chow. Mice were treated for one week or two weeks with cuprizone to 
analyze the apoptosis of oligodendrocytes and for six weeks to investigate the demyelination of 
the corpus callosum (CC). Body weights of the animals were measured weekly and transformed 
into percentage of initial weight. Therefore the mean of the initial body weights of each group was 
set to a hundred percent. 




To investigate the effects on remyelination, mice were fed with cuprizone for 5 weeks, then the 
cuprizone diet was stopped and mice were treated with either DMF or control for one week or 
three days.  
2.4.3. EAE induction 
Mice were subcutaneously injected with 100 µg recombinant mouse MOG protein1-117 emulsified 
in complete Freund’s adjuvant. Directly and 48h after immunization mice were intraperitoneally 
injected with 200 ng Pertussis toxin. Mice were scored daily according to a 0-5 scale score as 
described by (Weber et al., 2010). The rMOG1-117 was provided by the group of Claude C. Bernard 
(Monash University, Australia). 
2.4.4. DMF treatment 
Dimethyl fumarate (BG12) was synthesized at Biogen Idec. The compound was dissolved in a 0.8% 
hydroxypropyl methylcellulose solution (HPMC). The solution was stored at 8°C and used within a 
week. Cuprizone mice were treated twice daily with 15 mg/kg DMF or once daily with 100 mg/kg 
DMF. DMF was administered via oral gavage at a volume of 10 µl/g body weight. Control animals 
received 0.8% HPMC solution (control) as sham treatment.  
EAE mice were treated twice daily with 15 mg/kg DMF or control. Preventive treatment started 
two days prior to immunization. When mice were treated therapeutically, treatment started when 
mice showed an EAE score of two or higher. For clinical analysis mice were treated until day 50 or 
60 post immunization, for immunological analysis animals were treated until day 12 p.i. 
2.4.5. Extraction of mouse plasma 
Mice received 0.25% cuprizone and DMF or control for one week or for six weeks. To measure 
MMF levels, mice were sacrificed at the end of the experiment and blood samples were collected 
in a tube containing 4µl NaF solution (250 mg/ml in dH2O). Samples were centrifuged latest 10 min 
after collection. The plasma was stored at – 80°C and later analyzed by mass spectrometry.  
To measure the level of anti-MOG antibodies of mice during EAE, blood was collected from the 
facial vein into sera tubes and centrifuged at room temperature for 5 min at 10.0000 rpm. The 
plasma samples were stored at -20°C. 




2.4.6. Analysis of monomethyl fumarate (MMF) in plasma and brain 
MMF measurements were performed by the lab of Rob Scannevin (Biogen, Cambridge, USA). 
Therefore, 25 μL of either plasma or tissue homogenate samples were extracted by protein 
precipitation with acetonitrile containing 4C13-MMF as the internal standard. The aliquots of 
homogenization solution (plasma with 12.5 mg/mL of NaF) were added to the tissue samples. The 
tissue samples were homogenized at 6.5 m/s for 60 s on a Fast Prep Tissue Homogenizer prior to 
protein precipitation. The concentrations of MMF in plasma and brain samples were determined 
using qualified LC-MS/MS assays in the respective matrices. Data collections and integrations were 
accomplished using an API 5500 triple quadrupole mass spectrometer with a turbo ion spray 
interface (AB Sciex, Foster City, CA), and Analyst software (version 1.6.1). The peak area ratios of 
MMF relative to its internal standard were used to construct a standard curve using a quadratic 
regression with a 1/x2 weighting.  
2.4.7. Detection of anti-MOG antibodies 
For the measurement of anti-MOG Ab levels, a 96 well plate was coated with rMOG1-117 diluted 
1:200 (stock 2 mg/ml) over night at 4°C. The next day the plate was washed 3x with wash buffer 
and blocked with 200 µl/° RD1 buffer for 1h at RT shaking on a shaker plate (500 rpm). During this 
incubation time mouse plasma samples were diluted 1:40,500. Afterwards plates were washed 3x 
with wash buffer and 100 µl sample per well were added and incubated for 1.5 h at RT shaking on 
a shaker plate. Plates were washed 3x with wash buffer and 100 µl of a mixture including 
detection Ab (IgG mouse 2 mg/ml, diluted 1:6000 in RD1) und Streptavidin (diluted 1:40 in RD1) 
were added into each well and incubated for 1 h at RT in the dark. Plates were washed 4x with 
wash buffer and 100 µl of TMB solution were added and incubated until wells turned blue (15-20 
min). 4x wachen. The reaction was stopped with ELISA stop buffer. The OD was determined at 450 
nm with 540 nm wavelength correction using the iMark™ microplate reader. 
 
2.4.8. Analysis of immune cells ex vivo 
For the immunological readout, spleen and inguinal lymph nodes were isolated from control- or 
DMF-treated animals. After preparing a single cell suspension, immune cells were investigated ex 
vivo via flow cytometry.  




2.4.8.1. Preparation of single cell suspensions  
Single cell suspensions were prepared from spleen and lymph node for further investigation. 
Therefore, cells were disrupted by mechanical force through a sterile 70 μm cell strainer.  After 
two washing steps, splenocytes and lymphocytes were further processed dependent on the 
following experiment. Centrifugation steps with tubes were performed for 10 min at 300 x g and 
4°C and with plates for 8 min at 300 x g and 4°C. Cells were washed with PBS, FACS or MACS buffer 
depending on the further analysis. For a direct flow cytometric analysis of B and T cells, 
splenocytes and lymphocytes were washed with FACS buffer and transferred to a 96 well plate. 
For further isolation of B cells and T cells by magnetic-activated cell sorting (MACS), splenocytes 
were washed twice with 20 ml of MACS buffer. Cell numbers were determined prior to further 
analyses (see 2.4.7.4).  
2.4.8.2. Preparation of peripheral blood leukocytes from mice 
For analysis of the cell distribution in the blood under DMF treatment, blood samples were 
obtained by puncture of the facial vein. Several drops of blood were diluted in 300 μl PBS 
containing 1 mM EDTA and were transferred to a 5 ml FACS tube. 1 ml of FACS buffer was added 
and the tubes were centrifuged.  Erythrocytes were lysed by resuspending the pellet in 1 ml of BD 
Biosciences Pharm lyse™ solution (pre-diluted 1:10 in bidistilled water). Lysis was performed for 
3 min at RT and stopped by adding 3 ml of FACS buffer. FACS tubes with peripheral blood cells 
were centrifuged for 8 min at 300 x g at 4°C and the pellets were resuspended in 200 μl FACS 
buffer and transferred to a 96 well plate.  
2.4.8.3. Preparation of human peripheral blood mononuclear cells 
(PBMCs) 
To investigate the B cell frequency and activation under DMF treatment, blood samples were 
obtained from non-treated and DMF-treated MS patients. Afterwards, the collected blood was 
transferred into a 50 ml tube and 1:1 diluted with PBS. The blood/PBS mixture was carefully 
layered over 15 ml of Biocoll solution in a 50 ml tube and samples were centrifuged at 400 x g and 
20°C for 35 min without acceleration and brake. The mononuclear cell layer is gathered at the 
interphase and was carefully removed with a 10 ml volumetric pipette in a new 50 ml tube. Then 
50 ml RPMIcomplete were added and samples were centrifuged for 10 min at 300 x g and 4°C. 




Afterwards this washing step was repeated twice. Cell were counted in the Neubauer chamber 
and stored at –80°C in cryo medium. 
2.4.8.4. Cell counting  
For the determination of cell numbers, a Neubauer chamber was used. The cell suspension was 
diluted 1:10 in trypan blue (pre-diluted 1:10 in PBS) prior to counting to exclude dead cells. Four 
squares with a surface of 1 mm2 and a volume 0.1 μl each were counted for every sample. The 
concentration of cells in the original sample was calculated by the following formula:  
Cells counted/4 * 10 * 104 = cells/ml 
The total cell number was extrapolated to the sample volume. 
2.4.9. Flow cytometry  
The effects of DMF on different cell populations of the immune system were analyzed by flow 
cytometry. Single cell suspensions were stained with different combinations of fluorochrome-
labeled antibodies and cell populations were analyzed using a FACS LSR II and the BD FACSDiva 
Software 6.1.2. The staining procedure was always performed in 96 well round bottom plates, 
plates were centrifuged for 8 min at 300 x g and 4°C and cells were washed with 200 μl FACS 
buffer.  
2.4.9.1. FACS staining procedure of splenocytes, lymphocytes and 
peripheral blood leucocytes 
Isolated cells were centrifuged and washed with FACS buffer. Cells were resuspended in 30 μl 
blocking buffer, consisting of anti-CD16/CD32 antibody diluted 1:100 in FACS buffer, and 
incubated for 10 min at 4°C. The fluorochrome-labeled antibodies per staining were diluted 1:50 in 
FACS buffer and 30 μl of this master mix was added to each well (final dilution 1:100). The samples 
were incubated for 15 min at 4°C in the dark. Following incubation, the wells were filled with 
150 μl FACS buffer and plates were centrifuged. Cells were washed and resuspended in a mixture 
of 100 μl FACS buffer and 100 µl 4% PFA and incubated for 30 min. The fixed cells were then 
washed, resuspended in 200 µl FACS buffer and transferred to a 5 ml FACS tube. Fixed cells were 
analyzed by flow cytometry.  
Thawed human PBMCs were counted in a Neubauer chamber and 1x106 cells were transferred to 
a 5 ml tube. The samples were washed twice with FACS buffer and afterwards stained with 50 µl of 




a master mix containing fluorochrome-labeled antibodies (diluted 1:100 in FACS buffer). The 
samples were incubated for 15 min at 4°C in the dark and afterwards the samples were washed 
twice with 1 ml of FACS buffer. Finally cells were resuspended in 200 µl FACS buffer and analyzed 
by flow cytometry. 
2.4.9.2. Intracellular detection of Foxp3  
For the intracellular detection of Foxp3, splenocytes and lymphocytes were isolated as described 
above. Afterwards surface molecules were stained with the usual FACS staining procedure. But 
instead of the fixation step with PFA, cells were fixed in 100 µl Foxp3 fixation concentrate diluted 
1:3 in dilution buffer overnight at 4°C. The next day, 100 µl Perm/Wash™ buffer were added to 
each sample and plates were centrifuged. Afterwards the samples were washed two times with 
100 µl Perm/Wash™ buffer. The anti-Foxp3 antibody was diluted 1:100 in permeabilization buffer 
(prediluted 1:10 in bidistilled water) and 50 μl of the staining solution was added to each sample. 
Cells were incubated for 1 h at 4°C in the dark. After incubation, samples were washed two times 
with 100 µl of Perm/Wash™ buffer and once with FACS buffer. Finally, cells were resuspended in 
150 µl FACS buffer and transferred to FACS tubes. Samples were analyzed by flow cytometry. 
2.4.9.3. Intracellular detection of cytokines  
To investigate the effects of DMF on the frequency of IL-17- and IFNγ-producing T cells, 
splenocytes and lymphocytes were isolated from immunized mice, treated with control or DMF in 
vivo.  500,000 cells were seeded per well of a 96 well round bottom plate and stimulated with 
200 µl RPMIcomplete supplemented with ionomycin (0.5 µg/ml) and PMA (0.05 µg/ml) for 5 h at 37 
°C and 5% CO2. After 3 hours, 100 µl supernatant was collected and 1 µl GolgiStop™ was added to 
each sample. Afterwards, a surface staining was performed as described above. Cells were fixed in 
Cytofix/Cytoperm™ over night at 8°C. The next day, cells were washed twice with 100 µl 
Perm/Wash™ buffer (10x) diluted 1:10 in bidistilled water. Anti-IL-17 and anti-IFNγ antibodies 
were diluted 1:50 in Perm/Wash™ buffer and 50 μl of the staining solution was added to each 
well. Cells were incubated with the staining antibodies for 1 h at 4°C in the dark. Afterwards, the 
cells were washed twice with 150 µl of Perm/Wash™ buffer and plates were centrifuged. Cells 
were washed once with FACS buffer, resuspended in 150 μl of FACS buffer and analyzed by flow 
cytometry.  




2.4.10. Co-culture experiments 
2.4.10.1. Purification of CD4+ T cells and B cells 
For co-culture and ex-vivo experiments, CD4+ T cells or B cells were isolated from spleens of naïve 
C57BL/6 and 2D2 mice using MACS. Therefore, splenocytes were isolated as described above, but 
were washed immediately two times with 20 ml of MACS buffer and counted in a Neubauer 
Chamber. CD4+ T cells were purified using the CD4+ T cell isolation kit II (mouse, BD), B cells were 
purified using the Lineage panel (mouse, BD). LS columns and the QuadroMACSTM separator were 
used for separation of cells following the manufacturer’s instructions. After the purification, cells 
were washed in RPMIcomplete and. The specific cell number was either directly put into culture, CFSE 
labeled for further experiments (see 2.4.9.3) or co-cultured with B cells. 
2.4.10.2. rMOG binding assay 
To analyze the antigen-binding capacity of control-or DMF-treated B cells, 500,000 purified B cells 
were transferred into each well and incubated with 20 µg/ml rMOG1-117 labeled with DyLightTM 
405 for 2h at 37°C and 5% CO2. The rMOG1-117 was previously labeled with the use of the DyLightTM 
405 Antibody labeling kit following the manufacturer’s instructions. The labeling was performed 
by Ms. Elke Pralle (Department of Neuropathology, Göttingen). After the incubation, B cells were 
washed with 200 µl FACS buffer, afterwards resuspended in 200 µl FACS buffer and immediately 
analyzed by flow cytometry. 
2.4.10.3. Analysis of T cell proliferation by CFSE dilution 
 The effect of DMF-treated B cells on T cell proliferation in vitro was assessed by CFSE-staining of 
CD4+ T cells and subsequent flow cytometric analysis of CFSE dilution. CFSE can penetrate the 
intact cell membrane and binds irreversibly to intracellular proteins. Upon proliferation, the 
cytoplasm is shared between the two daughter cells and therefore the fluorescence intensity of 
CFSE is halved at each cell division. The CFSE profile of dividing cells can be analyzed by flow 
cytometry (Parish, 1999). CD4+ T cells were isolated from the spleen of naïve C57Bl/6J or 2D2 mice 
and purified by MACS separation (see 2.4.9.1). CD4+ T cells were counted in a Neubauer chamber 
(see 2.4.7.4) and cells were resuspended in 1 ml PBS. The CFSE stock solution (5 mM) was diluted 
1:1,000. Afterwards 200 µl of the CFSE solution was mixed with 800 µl of the cell suspension. Cells 
were then incubated for 15 min at 37°C in the dark. The staining reaction was stopped by addition 
of 20 ml cold RPMIcomplete and cells were centrifuged for 10 min at 1250 rpm and 4°C.  




The supernatant was discarded and cells were washed again in 20 ml of RPMIcomplete. Finally, cells 
were resuspended in RPMIcomplete and counted in a Neubauer chamber (see 2.4.7.4). The 
appropriate number of CFSE-labeled CD4+ T cells was then used in cultures for different 
proliferation experiments. T cell proliferation was analyzed by measuring the CFSE dilution using 
flow cytometry. 
2.4.10.4. Co-culture of B cells with CD4+ T cells  
To investigate the effect of DMF on the antigen-presenting function of B cells, co-culture assays 
were performed. Therefore, mice were immunized with rMOG1-117, treated with DMF or control 
until d12 p.i. in vivo and B cells were purified as described above. Splenic T cells were purified (see 
2.4.9.1) from 2D2 mice and labeled with CFSE (see 2.4.9.3). 500,000 B cells and 20,000 CFSE-
labeled T cells were seeded in 200 μl RPMIcomplete per well of a 96 well flat bottom plate. The co-
culture was then stimulated with 0, 25 or 50 µg/ml rMOG1-117. Cells were cultured for 72 h (37°C, 
5% CO2) and stained for T cell and B cell markers (see 2.4.8.1). Finally, T cell proliferation and 
expression of activation markers was measured by flow cytometry. 
2.4.11. In vitro stimulation of cytokine secretion 
To investigate effects of DMF on the proliferation of T cells ex-vivo, splenocytes were isolated from 
naïve animals treated with DMF or control for 19 days in vivo. T cells were purified by MACS 
separation and stained with CFSE as described above. Afterwards 20,000 T cells were transferred 
to each well of a 96 flat bottom well plate. This plate was previously coated with different 
concentrations of anti-CD3 and anti-CD28 antibodies over night at 8°C. T cells were incubated for 
72 h at 37°C and 5% CO2. T cell proliferation was investigated by FACS. 
2.4.12. Detection of cytokines using ELISA  
T cells are potent producers of a variety of cytokines. To analyze the DMF effects on this effector 
function, cytokine concentrations in the supernatant of stimulated single- and co-cultures were 
measured by ELISA.  
T cells were stimulated as described in 2.4.10 and IFNγ and GM-CSF secretion was analyzed. ELISA 
was performed using the Mouse IFNγ or GM-CSF ELISA MAX™ standard set. All standards and 
samples were run as duplicates. The capture antibody was diluted 1:200 in coating buffer and the 
96 well plate was coated with 100 µl/well over night at 4°C.  




The next day the plate was washed 3x with wash buffer and blocked with 200 µl/well RD1 buffer 
for 1h at room temperature shaking on a shaker plate (500 rpm). While the plate was being 
blocked standard solutions were prepared as described in the manufacturer’s instruction. 
Afterwards plates were washed 3x with wash buffer and 30 µl/well samples and standard dilutions 
were added and incubated over night at 4°C. The next day plates were washed 3x with wash 
buffer and 100 µl detection antibody (diluted 1:100 in RD1 buffer) were added. The plates were 
incubated for 2 h at room temperature with shaking (500 rpm). After incubation plates were 
washed 3x with wash buffer and 100 µl Avidin-HRP solution was added to each well, plate 
incubated for 30 min shaking (500 rpm) in the dark. Thereafter, plates were washed 4 times with 
wash buffer and 100 µl TMB substrate solution were added and incubated until wells turned blue 
in color (20-30 min). The reaction was stopped with ELISA stop buffer. The OD was determined at 
450 nm with 540 nm wavelength correction using the iMark™ microplate reader.  
2.4.13. Histology 
Sample preparation, histochemical and immunohistochemical stainings were performed by Ms. 
Katja Grondey, Mr. Jan Einar Albin and Ms. Mareike Gloth (Department of Neuropathology, 
University Medical Center Germany).  
2.4.13.1. Perfusion, tissue collection and sample preparation 
At the end of the in vivo experiments, mice were injected with a lethal dose of 14% chloral hydrate 
solution. After mice were checked for loss of consciousness and protective reflexes, the perfusion 
was performed by puncturing the left heart ventricle and rinsing the blood system first with PBS 
followed by a solution of 4% PFA. Brains, spleen and a part of the liver were collected and stored 
in 4% PFA at 8°C for 2 days post-fixation. Afterwards the samples were transferred to PBS and 
stored at 8°C for 24 h.  
For the cuprizone experiments, brains were sliced in 4 transverse sections. For EAE Experiments, 
the spinal cord was collected additionally and dissected into 10 to 12 sections. 
Before the paraffin embedding, the tissue was washed in water and then gradually dehydrated 
overnight. This was done by an automated tissue processor which is performing a graded 
alcohol/xylene/paraffin series. Paraffin blocks were sliced in 1 µm thick sections using a sliding 
microtome, and then mounted on glass slides.   




Prior to the start of the staining procedure, the sections had to be deparaffinized. Therefore the 
slices were incubated for at least 30 min at 54 °C and then rehydrated using the following steps. 
4x 10 min xylol  
1x 5 min isoxylol  
2x 5 min 100% isopropyl alcohol (IPA) 
1x 5 min 90% isopropyl alcohol (IPA) 
1x 5 min 70% isopropyl alcohol (IPA) 
1x 5 min 50% isopropyl alcohol (IPA) 
Distilled water  
After finishing the staining, the stained tissue sections were dehydrated by performing the 
described series above in reverse order.  This time the incubation time was only 2-3 min to avoid a 
weakening of the staining. As a final step the stained sections were mounted in DePex medium.  
2.4.14. Histochemical staining  
Hematoxylin and eosin (HE) staining  
To obtain a general overview of the tissue, a HE staining was performed. This staining was used to 
analyze inflammation and apoptosis. Hematoxylin stains basophilic nucleoproteins which results in 
blue colored cell nuclei. Eosin is binding acidophilic and basic extra- and intracellular proteins and 
marks thereby the parenchyma red.  For the staining, sections were deparaffinized and rehydrated 
as described above. Slides then were incubated in Mayer’s hemalaun for 5 min. Afterwards tissue 
sections were rinsed with dH2O. The sections were differentiated by shortly dipping them in 1% 
HCL-alcohol (1% HCl-alcohol in 90% isopropyl alcohol). The sections were then blued by rinsing 
them under tap water. For the staining of the parenchyma the slides were incubated in 1% eosin 
for 5 min (1% eosin in 70% isopropyl alcohol + 10 drops glacial acetic acid). Finally the sections 
were rinsed with dH2O, dehydrated and mounted in DePex medium. 
Luxol Fast Blue/Periodic Acid Schiff (LFB/PAS staining) 
LFB/PAS staining was performed to visualize myelin. Myelin is stained deep blue by LFB through 
the binding to lipoproteins. In contrast, PAS colors demyelinated parenchyma and also grey matter 




in pink.  At first, the sections were deparaffinized and rehydrated till the 90% IPA. Following the 
90% IPA, the slides were put directly into the LFB solution over night at 60°C.  The next day, the 
slides were washed in 90% IPA and differentiated by shortly dipping them into 0.05% lithium 
carbonate solution followed by a short dip into 70% IPA and a rinsing step with dH2O. Then the 
sections were incubated in 1% periodic acid for 5 min and rinsed for 5 min under flowing tap 
water. Slides were shortly washed with dH2O and afterwards incubated in Schiff’s solution for 20 
min.  Slides were washed under tap water for 5 min and incubated in Mayer’s hemalaun for 2 min. 
Slides were shortly dipped in dH2O and afterwards differentiated in 1% HCl-alcohol (1% HCl-
alcohol in 90% isopropyl). Sections were blued by rinsing under tap water for 10 min. Finally the 
tissue was dehydrated and mounted in DePex medium. 
Bielschowsky silver impregnation  
The Bielschowsky silver staining was used to analyze the axonal density. In this staining the axons 
appear black and the parenchyma yellow/ brownish. For this staining, the sections were 
deparaffinized and rehydrated.  Slides were washed 3 times in dH2O and then incubated for 20 
min in a 20% silver nitrate solution. The slides were washed with ddH2O and a 32% ammonium 
hydroxide solution was added dropwise to the used silver nitrate solution until the brownish 
solution becomes clear. The slides were incubated in the cleared silver nitrate/ammonium 
hydroxide solution for 15 min in the dark. After incubation, slides were transferred into ddH2O 
containing 3 drops of ammonium hydroxide. 10 drops of a developer solution were added to the 
silver nitrate/ammonium solution and slides were incubated until the sections showed a deep 
brown color and transferred into dH2O. The sections were incubated with a thiosulfate solution for 
2 min and subsequently rinsed with tap water. Slides were rehydrated and mounted in DePex. 
2.4.15. Immunohistochemical staining 
For the detection of specific cell markers, immunohistochemical stainings with antibodies were 
used. The signal visualization was performed with the avidin biotin method. Therefore, the tissue 
was incubated with specific primary antibodies specific for the antigen of interest. Afterwards a 
further incubation step followed with a biotin conjugated secondary antibody directed against the 
primary antibody. 
For a detailed list of the antibodies used for mouse tissue see Table 7. 




The visualization of the signal is obtained by the binding of the avidin coupled peroxidase (POX) 
and the oxidation of DAB by POX in the presence of H2O2. The fixation of the tissue can influence 
the binding efficacy of several antibodies. For a better antigen retrieval heat, acid or protease 
treatments were used. 
The immunohistological stainings were performed as follows: At first, the tissue was 
deparaffinized, rehydrated and rinsed 3x with dH2O. For the antigen retrieval with citric acid- or 
Tris-EDTA buffer, the slides were placed in polystyrene cuvettes. Those cuvettes were filled with 
1mM citric acid buffer (pH 6) or 1mM Tris-EDTA buffer (pH 9) and boiled 5 times in a microwave at 
800W for 3 min. 
The cuvettes were alternately filled with buffer or dH2O after each of the boiling steps. 
For the antigen retrieval with the proteinase solution the slides were incubated in a 37°C warm 
proteinase solution for 10 min and rinsed two times with dH2O. 
The slides were washed with PBS and incubated with 3% H2O2 for 20 min at 4°C to block 
endogenous peroxidase and reduce unspecific signals. Afterwards the slides were rinsed 3 times 
with PBS. The slides were pre-incubated with 10% FCS (in PBS) for 20 min at RT in a humidified 
chamber to prevent unspecific antibody binding. The slides were then incubated with the primary 
antibody (diluted in 10% FCS/PBS) over night at 4 °C in a humidified chamber. The slides were 
rinsed 3 times with PBS and incubated with biotin conjugated secondary antibody (diluted in 10% 
FCS/PBS) for 1 h at RT in a humidified chamber. The slides were rinsed with PBS for 3 times and 
incubated with 0.1% POX (diluted in 10% FCS/PBS) for 1 h at RT in a humidified chamber. 
Afterwards, the slides were again rinsed with PBS 3 times. For the signal development, the slides 
were put into DAB solution for several minutes and then rinsed 3 times with PBS. For the 
detection of mouse CD3 positive cells, the DAB signal was amplified with 2% copper sulfate in 0.9 
% sodium chloride for 10 min. The slides were washed with dH2O. The nuclei were counterstained 
with Meyer’s hemalaun solution for 30 sec followed by a short dip (1 s) in dH2O and a short wash 
step in dH2O. The differentiation was performed by a short dip into 1 % HCl-alcohol (1% HCl-
alcohol in 90% isopropyl alcohol). The blueing of the tissue was done by rinsing the slides under 
tap water for 10 min. The slides were dehydrated and mounted in DePex medium. 





Cuprizone: The number of cells stained with the corresponding antibodies was determined over 
the whole corpus callosum defined by an ocular morphometric grid at a 400x magnification and 
shown as cells/mm². For the determination of demyelinated areas of the corpus callosum, 
myelinated as well as demyelinated area of the corpus callosum was measured after LFB/PAS, PLP 
or MBP staining using ImageJ software. The percentage of demyelinated area was calculated 
relative to the whole area of the corpus callosum. 
EAE: The number of cells stained with the corresponding antibodies was determined in at least 6 
spinal cord sections defined by an ocular morphometric grid at a 400x magnification and shown as 
cells/mm². Inflammatory infiltrates were analyzed via a semi quantitative score (0 = no 
inflammation, 1 = slight inflammation, 2 = moderate inflammation, 3 = strong inflammation) after 
H&E staining in at least 6 spinal cord sections. To determine the white matter demyelination, 
myelinated and demyelinated areas were measured in at least 6 spinal cord cross sections after 
LFB-PAS staining using ImageJ software. The percentage of demyelinated area was calculated 
relative to the whole white matter area.  
2.6. Data analysis and statistics 
The software BDDiva and FlowJo 10.1 were used to analyze all flow cytometric data.  
Statistics were calculated using the software GraphPad Prism 6. Data were tested for normal 
distribution with the help of the D’Agostino & Pearson omnibus normality test. To compare two 
experimental groups, unpaired t-tests were used for parametric data and Mann-Whitney U tests 
for non-parametric data. For comparison of more than two experimental groups one way ANOVA 
with Sidak post test was used. Statistical significance was defined as p<0.05. Data in text and 








3.1. DMF treatment in the cuprizone model 
The oral agent DMF has beneficial effects on the relapse rate and different MRI parameters in 
RRMS patients (Fox et al., 2012; Gold et al., 2012). Several in vitro studies demonstrated the 
immunomodulatory effects of DMF and its metabolite MMF on peripheral immune cells like 
T cells, B cells and dendritic cells (Litjens et al., 2004a; Mrowietz and Asadullah, 2005; Treumer et 
al., 2003; Zhu and Mrowietz, 2001). Besides its immunomodulatory effects, the question if DMF 
exerts direct neuroprotective functions is unclear and the mode of action is still not fully 
understood (Moharregh-Khiabani et al., 2010; Scannevin et al., 2012b). To address the question if 
DMF has CNS intrinsic neuroprotective effects, independent of the peripheral immune system, the 
cuprizone model was used. 
3.1.1. DMF effects after short-term cuprizone intoxication 
Initial experiments were performed using two different dosages of DMF, 15 mg/kg twice daily and 
100 mg/kg once a day (data not shown), to determine the most appropriate treatment dosage in 
regard to efficacy. Data evaluation revealed that treatment with 15 mg/kg DMF twice a day was 
more effective and therefore only this dosage was used in subsequent experiments. The DMF 
short-term treatment was studied using 9 to 10 week old C57BL/6 mice which were fed with 
0.25% cuprizone and simultaneously treated with control (HPMC) or 15 mg/kg DMF twice a day for 
7 days or 2 weeks. Clinical and histological analyses were performed to assess control- and DMF-
treated mice.  
3.1.1.1. DMF treatment decreased the cuprizone-induced weight loss of 
C57BL/6 mice 
Mice which are fed with cuprizone show a profound body weight loss during the first two weeks of 
cuprizone exposure. Furthermore, DMF is known to exert gastrointestinal side effects, like 
abdominal pain, which may lead to a decreased feed uptake by mice. For these reasons, body 
weight of control- and DMF-treated mice was evaluated every day of cuprizone treatment. After 
4 days of 0.25% cuprizone treatment, control-treated mice lost significantly more weight 
compared to DMF-treated mice which persisted till 6 days after cuprizone treatment (Figure 1). 
The body weight of DMF-treated mice (day 4: 92.7% ± 1.46 %, day 5: 92.7% ± 1.2%, day 6: 





4: 87.4% ± 1.2%, p<0.05; day 5: 86.5% ± 1.8%, p<0.01; day 6: 86.4% ± 2.6%,p<0.05). No further 
weight loss was detectable at later time points (data not shown). 
 
 
Figure 1: Effect of DMF treatment on cuprizone induced weight loss. (A) Schematic representation of 
cuprizone and control or DMF treatment. C57BL/6 mice were fed with 0.25% cuprizone for 1 week and 
simultaneously treated with control or 15 mg/kg DMF twice a day. (B) Mice were daily monitored for body 
weight. DMF treatment significantly reduced the cuprizone-induced weight loss compared to controls. Data 
are represented as mean± SEM (n=12, *p<0.05, **p<0.01, unpaired t-test). 
 
3.1.1.2. Apoptotic cell death of oligodendrocytes is decreased by DMF 
treatment 
The apoptosis of oligodendrocytes begins shortly after the initiation of the cuprizone diet. 
Therefore, histological evaluations were performed after 7 days of cuprizone exposure (Hesse et 
al., 2010a). The number of apoptotic oligodendrocytes was analyzed after staining for caspase-3 
(Casp3), a marker for apoptotic cell death, and by morphological analysis (condensed and/or 
fragmented nuclei) of H&E (haematoxilin and eosin) stained sections (Figure 2). DMF treatment 
significantly decreased the number of apoptotic oligodendrocytes after 7 days of cuprizone 
exposure compared to control treated animals. The mean number of caspase-3 positive cells in the 
CC decreased from 106 ± 31 cells/mm2 in controls to 38 ± 13 cells/mm2 in DMF-treated animals 
(p<0.0001). Furthermore, the number of cells showing morphological signs of apoptosis was also 







Figure 2: DMF treatment reduces cuprizone-induced apoptosis of oligodendrocytes in the CC. For 
the analysis of DMF effects on the apoptosis of oligodendrocytes C57BL/6 mice were fed with 0.25% 
cuprizone for 1 week and simultaneously treated with control or 15 mg/kg DMF twice a day. Apoptotic cells 
in the CC were identified after caspase-3 staining and by morphological criteria in H&E staining. 
Representative sections of the CC are shown on the left and quantifications of cells on the right. 
Histological evaluation revealed that DMF treatment significantly decreases the apoptosis of 
oligodendrocytes under cuprizone diet. Data are represented as mean± SD (****p<0.0001, unpaired t-test). 
Inserts show an apoptotic cell in higher magnification. Scale bar = 50 µm 
 
3.1.1.3. Higher numbers of oligodendrocytes were present with DMF 
treatment 
Since DMF treatment significantly reduced the apoptosis of oligodendrocytes after 7 days of 
cuprizone treatment, it was investigated if DMF also influences the oligodendrocyte populations. 
The total number of oligodendrocytes including progenitor cells was analyzed after IHC staining for 
Olig2 and the number of mature oligodendrocytes after IHC staining for NogoA (Figure 3). DMF-
treated mice showed a significantly higher number of Olig2+ cells (235 ± 35 cells/mm2) in the CC 
compared to controls (156 ± 43 cells/mm2) (p<0.001). The number of NogoA+ cells was not 






Figure 3: DMF treatment increases number of oligodendrocytes after 7 days of cuprizone exposure. 
C57BL/6 mice were fed with 0.25% cuprizone and simultaneously treated with control or 15 mg/kg DMF 
twice a day for 7 days. The number of oligodendrocytes including progenitor cells (Olig2+) and mature 
oligodendrocytes (NogoA+) in the CC was analyzed after IHC staining. Representative sections of the CC are 
shown on the left and quantifications of cells on the right. The number of Olig2+ oligodendrocytes is 
significantly higher after DMF treatment whereas the number of mature oligodendrocytes is not altered. 
Data are represented as mean± SD (**p<0.01, unpaired t-test). Scale bar = 50 µm 
 
3.1.1.4. DMF application reduced the acute axonal damage after 7 days 
of cuprizone exposure 
Brain sections from control- or DMF-treated mice were stained for amyloid precursor protein 
(APP, a marker for acute axonal damage), reactive astrocytes (GFAP) and microglia/macrophages 
(Mac3) (Figure 4). After 7 days of cuprizone diet, almost no acute axonal damage, represented by 
the number of APP+ spheroids, was detectable in the CC of DMF-treated mice (0 ± 0.6 cells/mm2) 
compared to controls (6 ± 6 cells/mm2) (p<0.05). The number of GFAP+ cells and Mac3+ cells was 
slightly reduced by DMF treatment, but this effect was not statistically significant when compared 






Figure 4: DMF treatment reduces the acute axonal damage induced by cuprizone diet. C57BL/6 mice 
were fed with 0.25% cuprizone for 7 days and simultaneously treated with control or 15 mg/kg DMF twice a 
day. IHC of brain sections was performed to investigate the acute axonal damage (APP), number of reactive 
astrocytes (GFAP) and number of microglia/macrophages (Mac3) in the CC. Representative sections of the 
CC are shown on the left and quantifications of axonal spheroids and cells on the right. DMF treatment 
significantly reduces cuprizone-induced acute axonal damage compared to controls. The number of 
reactive astrocytes and microglia/macrophages were not significantly altered by DMF application. Data are 
represented as mean± SD (*p<0.05, Mann-Whitney U test). Scale bar = 50 µm 
 
3.1.1.5. Anti-apoptotic effect of DMF was not detectable after 2 weeks of 
cuprizone exposure 
The number of apoptotic oligodendrocytes was significantly reduced by DMF application after 
7 days of cuprizone diet. To investigate if this effect persists over a longer period of time, C57BL/6 
mice were fed with 0.25% cuprizone and simultaneously treated with control or 15 mg/kg DMF 
twice a day for 2 weeks. Apoptosis of oligodendrocytes was morphologically analyzed in H&E 





(Figure 5). DMF treatment slightly diminished the number of apoptotic cells after 2 weeks of 
cuprizone diet, but this effect was not statistically significant. The number of mature 
oligodendrocytes was comparable between control- and DMF-treated mice. In addition, DMF-
treated mice showed a higher number of Olig2+ cells, but in contrast to the results received after 
7 days of cuprizone exposure this effect was not statistically significant (data not shown). 
 
 
Figure 5: DMF treatment does not prevent apoptosis of oligodendrocytes in the CC after 2 weeks of 
cuprizone diet. The DMF effect on the apoptosis of oligodendrocytes was additionally analyzed after 
2 weeks of cuprizone treatment. (A) Schematic representation of cuprizone and control or DMF treatment. 
C57BL/6 mice were fed with 0.25% cuprizone for 2 weeks and simultaneously treated with control or 
15 mg/kg DMF twice a day.  (B) Histological staining was performed to analyze the number apoptotic cells 
(H&E) and number of mature oligodendrocytes (NogoA) in the CC. Representative sections of the CC are 
shown on the left and quantification of cells on the right. Histological evaluation revealed that DMF 
treatment does not significantly alter the apoptosis of oligodendrocytes and the number of mature 
oligodendrocytes after 2 weeks of cuprizone feeding. Data are represented as mean± SD. Inserts show an 






3.1.2. Long-term effects of DMF in the cuprizone mouse model 
DMF-treated mice showed reduced numbers of apoptotic oligodendrocytes and higher numbers 
of Olig2+ oligodendrocytes after 7 days of cuprizone exposure leading to the suggestion that DMF 
might also reduce cuprizone-induced demyelination of the CC. As the acute axonal damage was 
reduced by DMF after short term treatment, we were also interested in the axonal damage after 
long-term DMF treatment in the cuprizone model. To address this question, 9 to 10 week old 
C57BL/6 mice were fed with 0.25% cuprizone and simultaneously treated with control or 
15 mg/kg DMF twice a day for 6 weeks to study DMF effects on the demyelination of the CC as 
well as to analyze the axonal damage. Body weight of control- and DMF-treated mice was 
evaluated every week of cuprizone treatment (data not shown). However, the DMF effects seen 
on the body weight after one week of cuprizone treatment did not last in the long term therapy. 
3.1.2.1. Cuprizone-induced demyelination was not affected by DMF 
treatment 
Brain sections of control- and DMF-treated mice were examined and analyzed for demyelination 
of the CC after LFB-PAS and PLP (proteolipid protein) staining (Figure 6). The myelin in the LFB-PAS 
staining appears in blue and in PLP staining in brown. First, the area of the whole CC was 
measured and afterwards only the demyelinated regions. The demyelinated area is then indicated 
as percentage of the total CC. The LFB-PAS staining showed that the myelin appeared to be better 
preserved in the medial part of the CC of DMF-treated mice, but this effect did not reach statistical 
significance when compared to controls. The extent of demyelination in the PLP staining was 
similar between both groups. DMF effects on the cortical demyelination were also examined in 
DMF- and control-treated mice. However, the extent of demyelination was comparable between 






Figure 6: DMF application does not reduce demyelination in the CC. The demyelination of the CC was 
investigated after long-term cuprizone diet. (A) Schematic representation of cuprizone and control or DMF 
treatment. C57BL/6 mice were fed with 0.25% cuprizone and simultaneously treated with control or 
15 mg/kg DMF twice a day for 6 weeks. (B) LFB/PAS and PLP stainings were performed to measure the 
demyelinated area of the CC. Representative sections of the CC are shown above and the corresponding 
quantifications below. Demyelination is not significantly decreased by DMF treatment after 6 weeks of 
cuprizone exposure.  Data are represented as mean± SD. Scale bar = 1000 µm 
 
3.1.2.2. DMF treatment did not significantly reduce the acute axonal 
damage, astrogliosis and microglia/macrophages after 6 weeks 
of cuprizone intoxication  
Cuprizone-mediated demyelination leads to an increased accumulation of microglia/macrophages, 
acute axonal damage and higher numbers of astroglia. Mac3, APP and GFAP 





damage and the number of activated astrocytes (Figure 7). DMF treatment did not significantly 
alter the number of Mac3+ cells compared to controls. Additionally, the number of APP+ spheroids 
and GFAP+ cells was not significantly reduced by DMF treatment compared to controls. 
Nevertheless, a trend for less acute axonal damage and lower numbers of reactive astrocytes and 




Figure 7: No significant effect of DMF on acute axonal damage, astrogliosis and 
macrophage/microglial numbers after long-term cuprizone treatment. IHC staining for 
microglia/macrophages (Mac3), acute axonal damage (APP) and reactive astrocytes (GFAP) was performed 
of brain sections from C57BL/6 mice fed with 0.25% cuprizone and simultaneously treated with control or 
15 mg/kg DMF twice a day for 6 weeks. Representative sections of the CC are shown on the left and 
quantifications of cells on the right. The number of microglia/macrophages (Mac3), acute axonal damage 
and the number of reactive astrocytes are not significantly reduced by DMF application after 6 weeks of 






3.1.2.3. Axonal density was not significantly higher after DMF treatment 
In addition to the evaluation of the acute axonal damage, DMF effects were analyzed on the 
axonal density during cuprizone intoxication. Therefore a Bielschowsky staining was performed 
and axons were counted across the width of the CC under the cingulum bundle as depicted in 
Figure 8. The axonal density in the CC was tended to be higher in DMF-treated mice, but this effect 
did not reach statistical significance. 
 
Figure 8: DMF treatment shows no significant effect the axonal density. C57BL/6 mice were fed with 
0.25% cuprizone and simultaneously treated with control or 15 mg/kg DMF twice a day for 6 weeks. The 
number of axons in the CC was analyzed by Bielschowsky staining. Axons were counted over the width of 
the CC (white bar) under the cingulum bundle. Representative sections of the CC are shown on the left and 
quantification of axons on the right. The number of axons is not altered by DMF treatment. Data are 
represented as mean± SEM. Scale bar = 1000 µm, scale bar insert = 200 µm 
 
 
3.1.2.4. DMF treatment enhanced the number of mature 
oligodendrocytes after 6 weeks of cuprizone 
Olig2+ oligodendrocytes (including progenitor cells) were preserved by DMF treatment after 7 days 
of cuprizone diet whereas no difference in the number of Olig2+ oligodendrocytes and mature 
oligodendrocytes was observed after 2 weeks. To examine the number of mature 
oligodendrocytes after 6 weeks of cuprizone exposure, an IHC staining for NogoA was performed 
(Figure 9). Histological evaluation showed that the number of NogoA+ cells was significantly lower 
in controls (110 ± 38 cells/mm2) compared to DMF-treated animals (146 ± 21 cells/mm2) (p<0.05). 
The total number of oligodendrocytes (Olig2+ cells) was not altered by DMF treatment after 






Figure 9: Higher numbers of mature oligodendrocytes after 6 weeks of cuprizone exposure with 
DMF treatment. C57BL/6 mice were fed with 0.25% cuprizone and simultaneously treated with control or 
15 mg/kg DMF twice a day for 6 weeks. The number of mature oligodendrocytes (NogoA) in the CC was 
analyzed after IHC staining. Representative sections of the CC are shown on the left and quantification of 
cells on the right. The number of mature oligodendrocytes is significantly higher after DMF treatment. Data 
are represented as mean± SD (*p<0.05, unpaired t-test). Scale bar = 50 µm 
 
3.1.3. DMF effects after cuprizone withdrawal 
For the analysis of remyelination, C57BL/6 mice were fed with 0.25% cuprizone for 5 weeks to 
induce demyelination of the CC. This time point was chosen because endogenous remyelination 
already starts after 5 weeks of cuprizone exposure. After 5 weeks, cuprizone diet was stopped and 
mice were fed with normal chow and treated therapeutically with control or 15 mg/kg DMF twice 
a day for 3 days. Next to remyelination, analyses focused on the axonal damage and accumulation 
of microglia/macrophages. 
3.1.3.1. Remyelination was not enhanced by DMF treatment 
Naturally, the removal of cuprizone leads to rapid remyelination of the CC of mice. In the first 
experiment, remyelination was analyzed after 7 days of cuprizone withdrawal and control or DMF 
treatment (data not shown). Since remyelination was already far advanced at this time point, a 
shorter treatment period was chosen for further analyses. To investigate the potential of DMF to 
increase remyelination, C57BL/6 mice were fed with 0.25% cuprizone for 5 weeks to induce 
demyelination. Afterwards cuprizone diet was stopped and mice were treated with control or 
15 mg/kg DMF twice a day for 3 days. Remyelination was investigated after LFB-PAS staining 
(Figure 10). Both groups still showed the same extent of demyelination in the lateral region of the 
CC illustrating that DMF treatment could not increase the remyelination of the CC compared to 





PLP, MBP and CNPase. No significant difference between control- and DMF-treated animals was 
observed for these three myelin proteins (data not shown). The number of mature 
oligodendrocytes (NogoA+ cells) and the total number of oligodendrocytes (Olig2+ cells) was not 
altered by 3 days of DMF treatment after cuprizone withdrawal (data not shown). 
 
Figure 10: DMF has no effect on the remyelination of the CC. (A) Schematic representation of 
cuprizone and control or DMF treatment. C57BL/6 mice were fed with 0.25% cuprizone for 5 weeks. 
Afterwards cuprizone diet was stopped and mice were treated with control or 15 mg/kg DMF twice a day 
for 3 days. (B) LFB/PAS staining was performed to measure the demyelinated area of the CC. 
Representative sections of the CC are shown above and the corresponding quantification below. 
Remyelination is not significantly increased by 3 days of DMF treatment after cuprizone withdrawal. Data 
are represented as mean± SD. Scale bar = 1000 µm 
 
3.1.3.2. Acute axonal damage was diminished by DMF after 3 days of 
cuprizone withdrawal 
The effects of DMF on acute axonal damage and numbers of microglia/macrophages after 
cuprizone removal were investigated after IHC staining of brain sections from control- or DMF-
treated mice. Acute axonal damage was investigated by counting APP+ spheroids and phagocyte 





decreased by DMF (84 ± 53 cells/mm2) when compared to controls (190 ± 78 cells/mm2) (p<0.05). 
The accumulation of microglia/macrophages was comparable between both groups. 
 
Figure 11: DMF treatment decreases acute axonal damage after cuprizone withdrawal. C57BL/6 
mice were fed with 0.25% cuprizone for 5 weeks. Afterwards cuprizone diet was stopped and mice were 
treated with control or 15 mg/kg DMF twice a day for 3 days. IHC staining for acute axonal damage (APP) 
and the number of microglia/macrophages was performed. Representative sections of the CC are shown on 
the left and quantification of cells on the right. Acute axonal damage is significantly reduced by 3 days of 
DMF treatment after cuprizone withdrawal. Data are represented as mean± SD (*p<0.05, unpaired t-test). 
Scale bar = 50 µm 
 
3.1.4. MMF was detectable in the brain of DMF-treated mice 
An important feature of the cuprizone mouse model is the intact blood brain barrier (BBB) which 
allows the investigation of CNS intrinsic effects without the influence of the peripheral immune 
system. To analyze if DMF can pass the BBB and reaches the CNS, its metabolite MMF was 
measured in plasma and brain samples of control- and DMF-treated mice by mass spectrometry. 
MMF could be detected in the plasma and brain samples of DMF-treated mice after 7 days and 
was even slightly increased after six weeks of therapy (Figure 12). No MMF was found in the 
plasma and brain of controls. Mass spectrometry analysis was kindly performed by the lab of Rob 






Figure 12: MMF, the active metabolite of DMF, is present in the brain of DMF-treated mice. 
C57BL/6 mice were fed with 0.25% cuprizone and simultaneously treated with control or 15 mg/kg DMF 
twice a day for 7 days or 6 weeks. The amount of the DMF metabolite MMF was analyzed by mass 
spectrometry in plasma and brain. MMF can be detected in the plasma and brain of DMF-treated mice after 
7 days and 6 weeks whereas in control-treated mice MMF is not detectable. Data are represented as 
mean± SD (7 days n=6, 6 weeks n=4). 
 
3.1.5. DMF did not reduce apoptosis of oligodendrocytes in Nrf2 k.o. 
mice 
It is assumed that DMF exerts protective functions via the activation and stabilization of the 
transcription factor Nrf2, which activates antioxidant response pathways and thereby leads to a 
better protection of cells against oxidative stress (Linker et al., 2011; Scannevin et al., 2012c; 
Thiessen et al., 2010). To investigate if the DMF-mediated reduction of apoptotic oligodendrocytes 
after 7 days of cuprizone is dependent on Nrf2, apoptosis of oligodendrocytes was examined in 
Nrf2 k.o. mice. Similar to the first experiments, Nrf2 k.o. mice were fed with 0.25% cuprizone for 
7 days and simultaneously treated with control or 15 mg/kg DMF twice a day. Apoptosis of 
oligodendrocytes was analyzed in H&E stained tissue (Figure 13). Histological evaluation revealed 
that control-treated Nrf2 k.o. mice already showed reduced numbers of apoptotic cells when 
compared to C57BL/6 mice (Figure 2). The number of apoptotic cells was similar in control- and 






Figure 13: DMF treatment does not decrease apoptosis of oligodendrocytes in the CC of Nrf2 
k.o. mice. (A) Schematic representation of cuprizone and control or DMF treatment. Nrf2 k.o. mice were 
fed with 0.25% cuprizone for 7 days and simultaneously treated with control or 15 mg/kg DMF twice a day. 
(B) Apoptotic cells in the CC were identified by morphology in H&E staining. Representative sections of the 
CC are shown on the left and quantification of cells on the right. Histological evaluation revealed that the 
number of apoptotic oligodendrocytes is not reduced in Nrf2 k.o. mice by DMF treatment. Data are 
represented as mean± SD. Inserts show an apoptotic cell in higher magnification. Scale bar = 50 µm   
 
In summary, although DMF did not profoundly alter the extent of demyelination and 
remyelination, the number of oligodendrocytes was increased in DMF-treated animals over time. 
Whereas after short-term cuprizone exposure the overall number of oligodendrocytes including 
OPCs was increased with DMF treatment, after 6 weeks of cuprizone diet the number of mature 
oligodendrocytes was higher in DMF-treated animals compared to controls.  
DMF treatment reduced the acute axonal damage after 7 days of cuprizone treatment. Although 
this effect was not significant after 6 weeks of cuprizone diet, a trend towards less acute axonal 
damage in DMF-treated animals was observed. Nevertheless, therapeutic DMF treatment 
significantly decreased the number of damaged axons after 3 days of treatment following 






3.2. DMF effects in a B cell-mediated EAE model 
Besides the analysis of CNS intrinsic effects, further studies focused on peripheral effects mediated 
by DMF treatment. Therefore, DMF was analyzed in a B cell-mediated EAE model. 
The beneficial effects of the B cell-depleting agent rituximab in the therapy of RRMS emphasized 
the pathological role of B cells in the disease pathogenesis (Hauser et al., 2008b). Previous studies 
investigated the effects of DMF in more T cell-dependent EAE models, induced by immunization 
with MOG peptide. In this model, B cells do not extensively contribute to the disease pathogenesis 
demonstrated by the detrimental effects of rituximab in this EAE (Weber et al., 2010).  Therefore, 
the present study aimed to examine the effects of DMF on adaptive immune cells in an EAE model, 
induced by immunization with MOG protein, in which B cells contribute in a pathogenic manner. 
For the investigation of DMF-mediated effects, mice were treated once in a preventive setting,  
starting 2 or 7 days before immunization, or in a therapeutic regimen starting when mice showed 
an EAE score of 2 (hind limb weakness) or higher (Figure 14). 
 
 
Figure 14: Schematic representation of the experimental setup. C57BL/6 mice were immunized with 
100 µg rMOG1-117 and treated with 15 mg/kg DMF or control twice a day. Preventive treatment started 2 or 
7 days prior to immunization, therapeutic treatment when mice showed an EAE Score of 2 (hind limb 
weakness) or higher. For immunological evaluations mice were treated until day 12 and for clinical and 






3.2.1. DMF treatment decreased EAE severity and demyelination of the 
spinal cord 
To investigate the efficiency of DMF to improve B cell-mediated chronic EAE, C57BL/6 mice were 
immunized with rMOG1-117 and received oral treatment with either 15 mg/kg DMF or control twice 
a day. In the preventive setting, mice were treated until d60, in the therapeutic regimen until 
d50 p.i. (Figure 14). Clinical, histological and immunological analyses were performed to examine 
DMF-mediated alterations of adaptive and innate immunity. 
3.2.1.1. Preventive and therapeutic DMF treatment ameliorated the 
clinical course of EAE 
The initial experiments focused on the clinical effects mediated by DMF application. Hence, EAE 
score and body weight (data not shown) of immunized mice were monitored daily (Figure 15). 
Animals of the preventively treated groups showed an overall lower EAE severity compared to 
therapeutically treated animals. Data evaluations revealed that both preventive and therapeutic 
DMF treatment significantly ameliorated the disease course of mice (*p<0.05, **p<0.01). 
 
Figure 15: Clinical course of EAE is ameliorated by preventive and therapeutic DMF treatment. 
Clinical disease scores of chronic EAE in C57BL/6 mice, immunized with rMOG1-117 and treated with 
15 mg/kg DMF (black) or control (grey) twice a day. (A) Preventive DMF treatment significantly ameliorates 
the disease course as compared to control. Mice were treated from d-2 until d60. Data are represented as 
mean ± SEM (n=10 per group, *p<0.05, **p<0.01, Mann-Whitney U test). (B) Therapeutic DMF treatment 
started when mice showed an EAE Score of 2 (hind limb weakness) or higher. Therapeutic application of 
DMF significantly ameliorates the course of disease compared to control. Data are represented as mean ± 





3.2.1.2. Anti-MOG Ab titers were not altered by DMF application 
To evaluate the effects of DMF treatment on the humoral immune response, production of anti-
MOG Ab levels in the serum of rMOG1-117 immunized mice treated with 15 mg/kg DMF or control 
was determined weekly until day 42 p.i. (Figure 16). Animals which were treated with DMF 
preventively showed slightly increased Ab levels whereas the Ab level was slightly reduced in 
animals after the start of therapeutic DMF therapy compared to controls. Neither preventive nor 




Figure 16: Anti-MOG Ab serum levels remain constant under preventive and therapeutic DMF 
treatment. C57BL/6 mice were immunized with rMOG1-117 and treated with 15 mg/kg DMF (black) or 
control (grey) twice a day. Anti-MOG Ab serum levels were weekly determined by ELISA until day 42 p.i. 
Before analysis serum samples were diluted 1:40,500. (A) Preventive and (B) therapeutic DMF treatment do 
not alter anti-MOG Ab levels compared to controls. Preventive DMF treatment started 2 days before 
immunization and therapeutic DMF treatment started when mice showed an EAE Score of 2 (hind limb 
weakness) or higher. Data are represented as mean ± SEM (preventive control and DMF n=10, therapeutic 
control n=9, therapeutic DMF n=8). 
 
3.2.1.3. Demyelination and inflammation of the spinal cord was 
decreased by DMF  
DMF could significantly reduce the EAE severity in the preventive setting as well as in the 
therapeutic regimen. To study if DMF could also diminish the damage of the CNS, spinal cord 
sections of control-or DMF-treated mice were analyzed for demyelination, inflammation and the 
number of infiltrated cells. LFB-PAS staining was performed to measure the demyelinated area 





Additionally, spinal cord sections were examined for infiltrating B cells (B220), T cells (CD3) and 
macrophages (Mac3). Mice which were preventively treated with DMF showed no significantly 
reduced demyelination, inflammation or number of infiltrating cells compared to their controls. In 
contrast, demyelination was reduced in therapeutically DMF-treated mice (4.7% ± 0.9 %) 
compared to controls (14.0% ± 2.4 %) (p<0.05). Furthermore, therapeutic application of DMF 
significantly decreased inflammation from a mean inflammation score of 1.6 ± 0.2 in controls to a 
mean score of 0.7 ± 0.2 (p<0.01). The number of infiltrating Mac3+ cells was significantly 
diminished by therapeutic DMF treatment (217 ± 59 cells/mm2)  compared to controls 
(444 ± 102 cells/mm2) (p<0.05). Infiltrating B cell and T cell numbers were not significantly altered 







Figure 17: Spinal cord demyelination and infiltration is reduced after DMF treatment. Histological 
evaluation of C57BL/6 mice, immunized with rMOG1-117 and preventive or therapeutically treated with 
15 mg/kg DMF or control twice a day. Demyelination (LFB/PAS), inflammation (H&E) and immune cell 
infiltration of the spinal cord evaluated by B220-, CD3- and Mac3-immunohistochemistry 50 days 
(therapeutic) and 60 days (preventive) after immunization. Representative sections of therapeutic treated 
mice (left) and percentage of demyelinated white matter area, score of spinal cord inflammation (0 = no 
inflammation, 1 = slight inflammation, 2 = moderate inflammation, 3 = strong inflammation) and number of 
infiltrating immune cells/mm2 spinal cord (right). Therapeutic DMF treatment significantly reduces spinal 
cord demyelination and infiltration of cells. Data are represented as mean ± SEM (*p<0.05, **p<0.01, one 
way ANOVA with Sidak post test). Inserts show B220+ or CD3+ cells in higher magnification. 





3.2.2. DMF had opposing effects on B cells and T cells during the early 
phase of EAE 
DMF treatment ameliorated the clinical course of B cell-mediated chronic EAE and could also 
reduce the demyelination and inflammation of the spinal cord. To investigate if DMF-mediated 
effects already occur at the beginning of the disease, an earlier time point of EAE was chosen for 
immunological evaluations. Therefore, C57BL/6 mice were immunized with rMOG1-117 and 
preventively treated with 15 mg/kg DMF or control 2 or 7 days prior to immunization until day 12, 
a day of the disease onset (Figure 14).  
3.2.2.1. DMF treatment altered the activation and differentiation of 
T cells 
Effects of DMF on the activation and differentiation of T cells were evaluated by analyzing T cell 
molecules which reflect their activation state and subpopulations. 
3.2.2.1.1. DMF induced a shift in the local distribution of T cells 
Lymphopenia is an abnormally low level of lymphocytes and a common side effect of DMF therapy 
in MS patients (Longbrake et al., 2015). Therefore DMF effects on the cell frequency of immunized 
mice were analyzed in blood, lymph node and spleen 12 days after immunization. The frequencies 
of CD4+ T cells, CD8+ T cells, CD19+ cells (B cells) and CD11b+ cells (including 
monocytes/macrophages, granulocytes, dendritic cells) were analyzed by flow cytometry 
(Figure 18). Data evaluation revealed a significant decrease in the frequency of CD4+ T cells in 
DMF-treated animals (12.6% ± 1.5%) compared to control-treated animals (14.7% ± 1.8%). In 
contrast, the CD4+ T cell frequency was significantly increased in lymph node and spleen by DMF 
treatment from a mean of 20.0% ± 2.7% and 12.8% ± 2.4% respectively in controls to a mean of 
23.2% ± 3.0% and 15.4% ± 1.9% respectively in DMF-treated mice (p<0.05). The frequency of 
CD8+ T cells was also increased in the spleen of DMF-treated mice (8.9% ± 1.3%) compared to 
controls (7.1% ± 1.8%) (p<0.05). In the blood the frequency of CD8+ T cells was slightly decreased 
and in the lymph node slightly increased. The frequencies of CD19+ cells and CD11b+ cells were 






Figure 18: T cell frequencies in blood, lymph node and spleen are altered under DMF treatment at 
day 12 p.i. Cell frequencies of CD4+ T cells, CD8+ T cells, CD19+ cells and CD11b+ cells were analyzed by flow 
cytometry (A). C57BL/6 mice were immunized with rMOG1-117 and treated with 15 mg/kg DMF or control 
twice a day from d-7 until d12 p.i. (B) In vivo DMF treatment significantly reduces the frequency of 
CD4+ T cells in blood and increases the frequency of CD4+ T cells in lymph node and the frequencies of 






3.2.2.1.2. Reduced T cell activation upon DMF treatment 
Since DMF treatment significantly increased the T cell frequency in lymph node and spleen, the 
next experiment focused on the activation status of these T cells. DMF-induced changes in the 
activation of CD4+ T cells and CD8+ T cells were analyzed in lymph node and spleen from 
immunized mice treated with DMF or control until day 12 p.i. T cell activation was characterized 
by the expression of activation markers CD69 and CD25, samples were gated on CD4+ T cells and 
CD8+ T cells. The geometric mean fluorescence intensity (gMFI) of CD69 and CD25 was examined 
by flow cytometry (Figure 19). Data values were normalized to control (set 100%). The expression 
of CD69 on CD4+ T cells was significantly downregulated in lymph node and spleen by DMF 
treatment from a mean of 100.0% ± 8.9% and 100.0% ± 5.0% in controls to a mean of 
91.1% ± 4.5% and 92.2% ± 4.2% in DMF-treated mice (p<0.05, p<0.01). CD4+ T cells of the lymph 
node from DMF-treated mice also showed a reduced expression of CD25 compared to controls 
(92.2% ± 7.5% vs. 100.0% ± 6.3%) (p<0.05). CD25 expression on splenic CD4+ T cells remained 
unaltered by DMF. Furthermore, DMF treatment decreased the expression of CD69 on CD8+ T cells 
in lymph node and spleen from a mean of 100.0% ± 11.3% and 100.0% ± 3.9% in controls to a 









Next page  
Figure 19: DMF decreases the expression of activation markers on T cells. (A) The effects of DMF on 
the expression of CD69 on CD4+ T cells and CD8+ T cells and CD25 on CD4+ T cells in lymph node and spleen 
were analyzed ex vivo by flow cytometry. C57BL/6 mice were immunized with rMOG1-117 and treated with 
15 mg/kg DMF or control twice a da y from d-7 until d12 p.i. (B) Application of DMF significantly reduces 
the expression of CD69 on CD4+ T cells and CD8+ T cells in lymph node and spleen and the expression CD25 
on CD4+ T cells in the lymph node. Data are normalized to control and represented as mean ± SD (*p<0.05, 










3.2.2.1.3. DMF affected the T cell activation marker CD44 on CD4+ 
T cells and CD8+ T cells 
CD44 is an adhesion receptor and usually expressed on activated T cells and long-lived memory 
cells (Baaten et al., 2010a). It is involved in several biological processes like migration of cells and 
inflammation. To investigate the effects of DMF on the expression of CD44 on CD4+ T cells and 
CD8+ T cells, lymphocytes and splenocytes were isolated from immunized mice treated with DMF 
or control and were stained for CD4, CD8 and CD44. CD4+ T cells and CD8+ T cells were divided into 
CD44 high (CD44hi), CD44 intermediate (CD44int) and CD44 low (CD44low) T cells (Figure 20, Figure 
21). 
The frequency of CD44hi CD4+ T cells was significantly decreased in the spleen of DMF-treated mice 
(22.1% ± 1.8%) compared to controls (25.5% ± 4.1%) (p<0.05) whereas the frequencies of 
CD44int CD4+ T cells and CD44low CD4+ T cells remained unaltered by DMF application (Figure 20). 
DMF treatment did not significantly modify the frequencies of CD44hi CD4+ T cells, 







Figure 20: DMF decreases the frequency of CD44high CD4+ T cells. The effects of DMF on CD44 
expression were investigated in lymph node and spleen from rMOG1-117-immunized C57BL/6 mice treated 
with 15 mg/kg DMF or control twice a day from d-7 until d12 p.i. (A) The expression of CD44 on the surface 
of CD4+ T cells was analyzed by flow cytometry. Subsets of CD4+ T cells were classified as follows: CD44 high 
(CD44hi), CD44 intermediate (CD44int) and CD44 low (CD44low). (B) DMF treatment induces a shift in 
CD4+ T cell subpopulations towards fewer CD44 high cells in spleen. The frequencies of CD4+ T cell 
subpopulations in the lymph node remain unaltered under DMF treatment. Data are represented as mean 





Besides the analysis of CD4+ T cell subpopulations, DMF effects were also examined on 
subpopulations of CD8+ T cells. The frequency of splenic CD44hi CD8+ T cells was considerably 
reduced by DMF treatment (14.4% ± 2.0%) compared to controls (16.8% ± 1.8%) (p<0.05) whereas 
the frequencies of CD44int CD8+ T cells and CD44low CD8+ T cells were not altered by DMF 
application (Figure 21). DMF treatment did not significantly influence the frequencies of 







Figure 21: The frequency of CD44high CD8+ T cells is reduced by DMF. The effects of DMF on CD44 
expression were investigated in lymph node and spleen from rMOG1-117-immunized C57BL/6 mice treated 
with 15 mg/kg DMF or control twice a day from d-7 until d12 p.i. (A) The expression of CD44 on the surface 
of CD8+ T cells was analyzed by flow cytometry. Subsets of CD8+ T cells were classified as follows: CD44 high 
(CD44hi), CD44 intermediate (CD44int) and CD44 low (CD44low). (B) DMF treatment induces a shift in 
CD8+ T cell subpopulations towards fewer CD44 high cells in spleen. The frequencies of CD8+ T cell 
subpopulations in the lymph node remain unaltered under DMF treatment. Data are represented as mean 





3.2.2.1.4. DMF decreased IFNγ-producing CD4+ T cells numbers 
After the characterization of DMF effects on the T cell activation, it was further analyzed if DMF 
treatment could directly affect the differentiation of pro-inflammatory T cells. Effects of DMF on 
the frequency of IFNγ-producing CD4+ T cells and IL-17-producing CD4+ T cells were investigated by 
ex vivo stimulation of lymphocytes and splenocytes, isolated from control- or DMF-treated mice, 
with ionomycin and PMA respectively. Cytokine secretion was blocked and intracellular IFNγ and 
IL-17 staining was analyzed by flow cytometry (Figure 22). CD4+ T cells were investigated for IFNγ 
and IL-17 production. DMF significantly reduced the frequency of IFNγ-producing CD4+ T cells in 
lymph node and spleen from a mean of 2.1% ± 0.9% and 6.8% ± 2.2% in controls to a mean of 
1.0% ± 0.4% and 4.4% ± 0.9% in DMF-treated mice (p<0.01). DMF treatment slightly reduced IL-17-






Figure 22: DMF treatment reduces the differentiation of IFNγ+ T cells and IL17+ T cells Splenocytes 
and lymphocytes were isolated from C57BL/6 mice immunized with rMOG1-117 and treated with 15 mg/kg 
DMF or control twice a day from d-7 until d12 p.i. (A) After ex vivo stimulation with Ionomycin and PMA the 
proportions of IFNγ-producing (IFNγ+) and IL17-producing (IL17+) T cells were evaluated by intracellular 
cytokine staining and flow cytometry. (B) In vivo treatment with DMF significantly decreases the frequency 
of IFNγ+ T cells in lymph node and spleen while the frequencies of viable CD4+ T cells and IL17+ T cells 





3.2.2.1.5. The frequency of regulatory T cells was not influenced by 
DMF treatment 
For the investigation of DMF effects on anti-inflammatory T cells, the frequency of regulatory 
T cells among lymphatic and splenic CD4+ T cells was determined in immunized mice treated with 
either DMF or control. Regulatory T cells are characterized by the expression of the transcription 
factor Foxp3 and additionally by the surface marker CD25 (Hori et al., 2003). Thus, surface staining 
for CD4, CD25 and intracellular staining of Foxp3 was performed and the frequencies of Foxp3+ 
and Foxp3+ CD25+ cells within the population of CD4+ T cells were analyzed via flow cytometry. As 
seen in Figure 23, data analysis revealed that DMF treatment did not majorly affect the frequency 



































Figure 23: DMF treatment does not alter regulatory T cell frequencies. Splenocytes and lymphocytes 
were isolated from C57BL/6 mice immunized with rMOG1-117 and treated with 15 mg/kg DMF or control 
twice a day from d-7 until d12 p.i. The frequencies of Foxp3+ T cells and Foxp3+ CD25+ T cells were assessed 
by intracellular and surface staining and flow cytometry. In vivo treatment with DMF does not alter the 
frequencies of Foxp3+ T cells and Foxp3+ CD25+ T cells in lymph node and spleen. Data are represented as 





3.2.2.1.6. In vivo DMF-treated T cells showed reduced proliferation 
upon antigen-independent activation in vitro 
To investigate whether DMF treatment in vivo could alter the functional properties of T cell 
activation and proliferation in vitro, T cells were isolated from naïve C57BL/6 mice treated 
with 15 mg/kg DMF or control for 19 days. The purified T cells were labeled with the fluorescent 
dye CFSE and stimulated with anti-CD3/CD28 in an antigen-independent manner. CFSE 
fluorescence intensity is halved with each cell division and by analyzing the CFSE profile of T cells 
by flow cytometry, the number of cell divisions can be measured (Parish, 1999).  
Proliferation of CD4+ T cells and CD8+ T cells was divided in following proliferation rates: low 
proliferation, intermediate proliferation and high proliferation (Figure 24B). The total proliferation 
of in vivo DMF-treated CD4+ T cells, stimulated with 0.125 µg/ml anti-CD3, was significantly 
reduced compared to controls (76.4% ± 3.8% vs. 89.2% ± 2.7%) (p<0.001). This reduced 
proliferation was also demonstrated by the number of cell divisions. DMF-treated CD4+ T cells 
showed an increased frequency of cells with low proliferation rate compared to controls (DMF: 
38.3% ± 3.5% vs. control: 22.7% ± 7.0%) (p<0.01) and reduced frequency of cells with high 
proliferation rate (DMF: 13.9%± 3.7% vs. control: 36.9% ± 12.3%) (p<0.001). DMF-treated 
CD4+ T cells, stimulated with 0.25 µg/ml anti-CD3, showed only a significant reduction in the 
frequency of cells with high proliferation rate (DMF: 30.6% ± 12.9% vs. control: 46.4% ± 10.7%) 
(p<0.01). The frequency of CD4+ T cells with low proliferation rate, stimulated with 0.25 µg/ml 
anti-CD3, and the frequencies CD4+ T cells with intermediate proliferation rate, stimulated with 
0.125 µg/ml anti-CD3 or 0.25 µg/ml anti-CD3, were not significantly altered by DMF treatment. 
In vivo DMF treatment also reduced the total proliferation of CD8+ T cells, stimulated with 
0.125 µg/ml anti-CD3, when compared to control-treated CD8+ T cells (86.9% ± 3.4% vs. 
94.6% ± 0.9%) (p<0.0001) (Figure 24B). This decreased proliferation was also demonstrated by the 
number of cell divisions. DMF-treated CD8+ T cells showed an increased frequency of cells with 
low proliferation rate compared to controls (DMF: 27.5% ± 5.6% vs. control: 9.6% ± 4.6%) (p<0.05) 
and reduced frequency of cells with high proliferation rate (DMF: 28.1% ± 8.4% vs. control: 
61.3%± 12.4%) (p<0.0001). The frequency of CD8+ T cells with intermediate proliferation rate, 





Proliferation of CD8+ T cells, stimulated with 0.25 µg/ml anti-CD3, was neither changed totally nor 
in single proliferation rates by DMF treatment.  
Besides the analysis of proliferation, T cell differentiation of proliferating T cells was analyzed by 
the production of IFNγ and GM-CSF measured by ELISA (Figure 24C). DMF-treated T cells, 
stimulated with 0.125 µg/ml anti-CD3, secreted significantly less IFNγ when compared to controls 
(DMF: 2844 ± 578 pg/ml vs. control: 3851 ± 845 pg/ml) (p<0.05). In vivo DMF treatment of T cells 
also significantly reduced the production of GM-CSF in vitro from mean secretion of 3553 ± 
796 pg/ml by control-treated T cells to a mean secretion of 2404 ± 1194 pg/ml by DMF-treated 
T cells (p<0.05). In vitro IFNγ production of T cells stimulated with 0.25 µg/ml anti-CD3 and 
GM-CSF production of T cells stimulated with 0.125 µg/ml anti-CD3 was not altered by DMF 







Figure 24: Proliferation of in vivo DMF-treated T cells is decreased after antigen-independent 
stimulation. T cells were purified from the spleens of naïve C57BL/6 mice treated with 15 mg/kg DMF or 
control twice a day for 19 days. In vitro, these T cells were stimulated with 0, 0.125 or 0.25 µg/ml anti-CD3 
and 5µg/ml anti-CD28 to induce T cell proliferation. (A) Proliferation of CD4+ T cells and CD8+ T cells was 
analyzed by flow cytometry. Representative FACS plots for CD4+ T cells and CD8+ T cells stimulated with 
0.125 µg/ml anti-CD3 and 5 µg/ml anti-CD28 are shown. (B) In vivo DMF-treated T cells proliferate 
significantly less after antigen-independent stimulation compared to controls. Data are represented as 
mean ± SD (n=4, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA with Sidak post test, two-
way ANOVA with Turkey multiple comparison test) (C) IFNγ and GM-CSF production by control- or DMF 
treated T cells stimulated with 0, 0.125 or 0.25 µg/ml anti-CD3 and 5 µg/ml anti-CD28 was determined by 
ELISA. T cells treated with DMF produce significantly less IFNγ and GM-CSF compared to control-treated 






3.2.2.2. DMF treatment increased the antigen-presenting function of 
B cells 
After the investigation of DMF effects on T cells, it was analyzed how DMF influences pathogenic 
B cells which contribute to the disease pathogenesis in this EAE model. The activation, function 
and phenotype of B cells were investigated via flow cytometry and co-culture experiments. 
3.2.2.2.1. DMF application increased MHC-II expression on B cells  
The next set of experiments investigated DMF-induced alterations in B cell subpopulations, 
activation state and effector functions. Therefore, rMOG1-117 immunized mice received daily oral 
treatment with either 15 mg/kg DMF or control from d-7 until d12 p.i. The activation state of 
B cells was analyzed ex vivo via the expression of MHC-II and the co-stimulatory molecules CD80, 
CD86 and CD40 in lymph node and spleen by flow cytometry (Figure 25). MHC-II expression was 
significantly enhanced on B cells in lymph nodes of DMF-treated mice from a mean of 3653 ± 
714 gMFI in controls to a mean of 4538 ± 620 gMFI in DMF-treated animals. The expression of 
CD80, CD86 and CD40 on lymphatic and splenic B cells as well as MHC-II expression on splenic 
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Figure 25: MHC-II expression on B cells is increased after DMF treatment. For the analysis of DMF 
effects on B cell activation, splenocytes and lymphocytes were isolated from C57BL/6 mice immunized with 
rMOG1-117 and treated with 15 mg/kg DMF or control twice a day from d-7 until d12 p.i. (A) The expression 
of MHC-II and co-stimulatory molecules CD80, CD86 and CD40 on B cells (B220+ CD19+) was analyzed by 
flow cytometry. (B) Data evaluation revealed that DMF significantly increases the expression of MHC-II on 
B cells of the lymph node whereas the co-stimulatory molecules remain mostly unaltered. Data are 










3.2.2.2.2. The expression of activation markers was not influenced 
by DMF treatment 
To further investigate the DMF effect on B cell activation, the expression of the activation markers 
CD69 and CD25 as well as the expression of the antigen-specific activation marker Fas (CD95) were 
measured on B cells from DMF- or control-treated mice. Therefore lymph nodes and spleen were 
isolated from immunized mice treated with either 15 mg/kg DMF of control and B cell activation 
markers were analyzed by flow cytometry (Figure 26). The expression of CD69, CD25 and Fas on 
B cells isolated from lymph node and spleen was comparable between DMF-treated and control-
treated mice.  
 
 
Figure 26: Expression levels of activation markers on B cells remain constant after DMF treatment. 
For the analysis of DMF effects on B cell activation, splenocytes and lymphocytes were isolated from 
C57BL/6 mice immunized with rMOG1-117 and treated with 15 mg/kg DMF or control twice a day from d-7 
until d12 p.i. The expression of activation marker CD69, CD25 and Fas (CD95) on B cells (B220+ CD19+) was 
analyzed by flow cytometry. DMF treatment does not significantly alter the expression of activation 





3.2.2.2.3. DMF treatment shifted B cell subsets towards more 
CD21int B cells 
After DMF effects were investigated on B cell activation, it was further analyzed if DMF also affects 
specific subpopulations of B cells. Murine B cells can be divided by distinct expression pattern of 
the surface molecules CD21 and CD23. Using flow cytometry, CD21hi CD23+ B cells can be 
distinguished from CD21int CD23+ B cells and CD21- CD23- B cells (Shen and Fillatreau, 2015). 
CD21hi CD23+ B cells, CD21int CD23+ B cells and CD21- CD23- B cells will be further referred to as 
transitional, follicular and immature B cells, respectively, in this work.  
To examine the effects of DMF on B cell subpopulations in spleen and bone marrow, the 
proportion of transitional, follicular and immature B cells were analyzed within the proportion of 
B220+ CD19+ B cells by flow cytometry (Figure 27). DMF treatment profoundly altered B cell 
subpopulations in immunized mice. DMF mediated a shift towards more follicular B cells and 
fewer transitional B cells in spleen, whereas the immature B cells in the bone marrow remained 
constant. Transitional B cells were decreased in DMF-treated animals (12.9% ± 2.5%) when 
compared to controls (14.9% ± 0.9%) (p<0.05). Follicular B cells were increased in DMF-treated 







Figure 27: DMF induces a shift in B cell subpopulations. The effects of DMF B cell subpopulations were 
investigated in spleens from rMOG1-117-immunized C57BL/6 mice treated with 15 mg/kg DMF or control 
twice a day from d-7 until d12 p.i. The expression of CD21 and CD23 on the surface of B cells (B220+ CD19+) 
was analyzed by flow cytometry. Subsets of B cells were classified as follows: CD21hi CD23+ B cells 
(transitional B cells), CD21int CD23+ B cells (follicular B cells) and CD21- CD23- B cells (immature B cells). DMF 
treatment induces a shift in B cell subpopulations towards fewer transitional and more follicular B cells in 
spleen. Data are represented as mean ± SD (*p<0.05, unpaired t-test). 
 
3.2.2.2.4. B cell phenotypes were not altered under DMF treatment 
Investigation of DMF effects on B cell subpopulations revealed that DMF treatment enhanced the 
frequency of follicular B cells, which reside in lymphoid follicles inside the spleen. Additionally, 
B cells can be divided in more specific phenotypes. Figure 28 shows the DMF effects on the 
following B cell phenotypes: immature naïve B cells (CD23-, IgM+, IgD-), mature naïve B cells 
(CD23+, CD38, IgM-, IgD+), memory B cells (B220high, CD38+, IgD-), regulatory B cells (CD1dhigh, 
CD5+), germinal center B cells (CD37+, GL7+) and antigen-activated B cells (CD27+, CD69+, CD80+, 
MHC-IIhigh).  
To analyze whether DMF treatment in vivo could affect specific phenotypes of B cells, B cells were 





d-7 until d12 p.i. The purified B cells were analyzed and phenotypes distinguished by flow 
cytometry using the surface markers described above (Figure 28). DMF-treated animals displayed 
slightly lower frequencies of immature naïve and germinal center B cells. The frequencies of 
antigen-activated and regulatory B cells were slightly increased by DMF treatment. Nevertheless, 
these effects did not reach any statistically significance. The frequencies of mature naïve and 
memory B cells remained unaltered by DMF. 
 
 
Figure 28: B cell phenotypes are not significantly affected by DMF treatment. B cells were purified 
from the spleens of C57BL/6 mice immunized with rMOG1-117 and treated with 15 mg/kg DMF or control 
twice a day from d-7 until d12 p.i. The expression of B220, CD1d, CD5, CD23, CD27, CD37, CD38, CD69, 
CD80, GL-7, IgD, IgM and MHC-II on the surface of B cells was analyzed by flow cytometry. Subsets of B cells 
were classified as follows: immature naïve B cells (CD23-, IgM+, IgD-), mature naïve B cells (CD23+, CD38, 
IgM-, IgD+), memory B cells (B220high, CD38+, IgD-), regulatory B cells (CD1dhigh, CD5+), germinal center B cells 
(CD37+, GL7+) and antigen-activated B cells (CD27+, CD69+, CD80+, MHC-IIhigh). FACS evaluation revealed that 
these B cell phenotypes are not significantly influenced by DMF application in vivo. Data are represented as 






3.2.2.2.5. DMF did not alter the frequency of rMOG1-117-binding 
B cells 
As a first functional analysis of in vivo control- or DMF-treated B cells, an rMOG-binding assay was 
performed to examine the antigen-binding capacity of B cells. Purified B cells of control- or DMF-
treated mice were then incubated with fluorescence-labeled rMOG for 2 hours and the frequency 
of B cells which had bound to rMOG was analyzed by flow cytometry (Figure 29). Data evaluation 
revealed that in vivo DMF treatment did not significantly alter the rMOG-binding capacity of B cells 
in vitro. 
 
Figure 29: DMF has no effect on the rMOG1-117-binding capacity B cells. B cells were purified from the 
spleens of C57BL/6 mice immunized with rMOG1-117 and treated with 15 mg/kg DMF or control twice a day 
from d-7 until d12 p.i. In vitro, these B cells were incubated with fluorescence-labeled rMOG1-117 and 
frequency of rMOG-binding B cells was evaluated by flow cytometry. In vivo treatment with DMF does not 
influence the antigen-binding capacity of B cells. Data are represented as mean ± SD. 
 
3.2.2.2.6. In vivo DMF-treated B cells promoted antigen-dependent 
T cell proliferation in vitro  
In a next experiment it was investigated how DMF affects the antigen-presenting functions of 
B cells. Therefore a co-culture experiment with control- or DMF-treated B cells and 2D2 T cells was 
performed to analyze B cell-mediated effects on T cell proliferation and T cell differentiation in 
vitro. Immunized C57BL/6 mice were treated with 15 mg/kg DMF or control from d-2 until 
day12 p.i. B cells were purified from the spleens of control- or DMF-treated C57BL/6 mice. 
Afterwards, these purified B cells were co-cultured with unlabeled or CFSE-labeled T cells isolated 
from naïve 2D2 mice and stimulated with rMOG1-117. T cell proliferation and differentiation were 





The first co-culture experiment investigated whether DMF treatment in vivo could alter the 
antigen-presenting functions of B cells. Therefore in vivo control- or DMF-treated B cells were co-
cultured with CFSE-labeled 2D2 T cells and stimulated with 0, 25 or 50 µg/ml rMOG1-117. B cells 
with a more potent antigen-presenting function induce a higher activation and proliferation of 
2D2 T cells. Figure 30 illustrates the DMF-mediated effects on the antigen-presenting function of 
B cells measured indirectly by T cell proliferation after 65 h. 
To acquire a more detailed analysis of DMF-induced effects, the proliferation of 2D2 T cells was 
divided in different proliferation rates. A low proliferation rate would therefore indicate a weak 
antigen-presenting function of B cells whereas high proliferation rate would indicate a more 
potent antigen-presenting function of B cells. The impact of DMF treatment on the antigen-
presenting function of B cells and thereby on 2D2 T cell proliferation is shown in Figure 30B. The 
total proliferation of 2D2 T cells co-cultured with in vivo DMF-treated B cells was significantly 
enhanced compared to controls (25 µg/ml rMOG1-117: ctrl 13.6% ± 2.5% vs. DMF 18.7% ± 4.4%, 
50 µg/ml rMOG1-117: ctrl 16.8% ± 3.6% vs. DMF 24.2% ± 4.2%) (p<0.05, p<0.01). When compared to 
control, DMF-treated B cells increased the frequency of 2D2 T cells with low proliferation rate 
(50 µg/ml rMOG1-117: ctrl 5.6% ± 0.5% vs. DMF 6.2% ± 0.7%, p<0.05), the frequency of 2D2 T cells 
with intermediate proliferation rate (50 µg/ml rMOG1-117: ctrl 5.8% ± 1.6% vs. DMF 8.2% ± 1.1%, 
p<0.05) and the frequency of 2D2 T cells with high proliferation rate (25 µg/ml rMOG1-117: ctrl 
4.4% ± 0.7% vs. DMF 7.4% ± 2.1%, p<0.001; 50 µg/ml rMOG1-117: ctrl 5.4% ± 1.6% vs. DMF 
8.2% ± 2.3%, p<0.01). The frequencies of 2D2 T cells with low and intermediate proliferation rate 
stimulated with 25 µg/ml rMOG1-117 were not significantly altered by DMF-treated B cells when 
compared to 2D2 T cells co-cultured with control-treated B cells.  
Additionally to the analysis of 2D2 T cell proliferation, co-cultured B cells were analyzed for MHC-II 
expression by flow cytometry (Figure 30C). In accordance with the ex vivo staining of B cells 
(Figure 25), MHC-II expression was slightly increased on DMF-treated co-cultured B cells, 
stimulated with 25 µg/ml rMOG1-117, when compared to control-treated B cells.  Nevertheless, this 






Figure 30: In vivo DMF treatment enhances the antigen-presenting function of B cells. To investigate 
the effects of DMF on the antigen-presenting function, B cells were purified from C57BL/6 mice immunized 
with rMOG1-117 and treated with 15 mg/kg DMF or control twice a day from d-2 until d12 p.i. These isolated 
B cells were then co-cultured with CFSE-labeled 2D2 T cells and stimulated with 0, 25 or 
50 µg/ml rMOG1-117. (A,B) The proliferation was analyzed by flow cytometry in the presence of either 
control- or DMF-treated B cells. Proliferation of 2D2 T cells is significantly increased when these are co-
cultured with DMF-treated B cells. (C) Simultaneously, MHC-II expression was analyzed on co-cultured 
B cells via flow cytometry. MHC-II is not significantly upregulated on B cells isolated from DMF-treated 
mice. Data are represented as mean ± SD (n=5, *p<0.05, **p<0.01, ***p<0.001, two-way ANOVA).  
 
3.2.2.2.7. In vivo DMF-treated B cells do not influence 
differentiation of IFNγ-producing T cells 
The first co-culture experiment demonstrated that 2D2 T cell proliferation could be amplified by 
in vivo DMF treatment of B cells. Hence, it was interesting to further analyze the fate of these high 
proliferating 2D2 T cells. To address this question, the differentiation of 2D2 T cells in vitro was 
analyzed in another co-culture system. The co-culture assay was performed as described in 





After 65 hours, 2D2 T cells were treated with ionomycin and PMA, cytokine secretion was blocked 
and intracellular IFNγ staining was analyzed by flow cytometry. As depicted in Figure 31, there was 
no difference in the frequency of IFNγ+ T cells between 2D2 T cells which were co-cultured with 
control- or DMF-treated B cells. 
 
 
Figure 31: In vivo DMF-treated B cells do not alter T cell differentiation in vitro. B cells were purified 
from C57BL/6 mice immunized with rMOG1-117 and treated with 15 mg/kg DMF or control twice a day from 
d-2 until d12 p.i. These isolated B cells were then co-cultured with CFSE-labeled 2D2 T cells and stimulated 
with 25 or 50 µg/ml rMOG1-117. The differentiation of IFNγ-producing (IFNγ+) T cells was analyzed by 
intracellular staining and flow cytometry in the presence of either control- or DMF-treated B cells. The 
frequency of IFNγ+ T cells is not altered in the presence of DMF-treated B cells. Data are represented as 
mean ± SD. 
 
3.2.3. DMF effects on human B cells 
We could observe that DMF treatment induced profound alterations of B cell functions in mice. To 
study if these DMF effects could also partly be seen on human B cells, a FACS analysis of B cells 
from non-treated MS patients (MS control) and DMF-treated MS patients (MS DMF) was 
performed. 
3.2.3.1. DMF treatment enhanced MHC-II expression on human B cells 
For the analysis of B cells, PBMCs isolated from MS patients were stained for CD19, MHC-II, CD80 
and CD40 analyzed via flow cytometry (Figure 32). MHC-II expression was significantly increased 





13078 ± 2199 gMFI vs. MS control 10592 ± 1428 gMFI) (p<0.05). The frequency of B cells and 
expression of CD80 and CD40 was comparable between DMF- and non-treated MS patients.  
 
Figure 32: DMF effects on B cells of MS patients. PBMCs were isolated from non-treated (control) or 
DMF-treated MS patients. The frequency of B cells and expression of MHC-II and co-stimulatory molecules 
CD80 and CD40 on B cells (CD19+) was analyzed by flow cytometry (A). Data evaluation revealed that DMF 
significantly increases the expression of MHC-II on B cells of DMF-treated MS patients whereas the B cell 
frequency and expression of co-stimulatory molecules remain mostly unaltered (B). Data are represented as 






In summary, DMF treatment in a B cell-mediated EAE model significantly ameliorated the disease 
course and reduced demyelination and inflammation of the spinal cord. Furthermore, T cell 
activation, pro-inflammatory T cell differentiation and antigen-independent proliferation of T cells 
was significantly decreased under DMF treatment during the early phase of EAE. In contrast, DMF 
increased MHC-II expression, the frequency of follicular B cells and antigen-presenting properties 
of B cells. These results could also partly be observed in DMF-treated MS patients whose B cells 







The oral agent dimethyl fumarate (DMF) has been approved for the therapy of RRMS. Besides its 
beneficial effects on relapse rate and MRI lesion formation, DMF and its metabolite MMF have 
been shown to exert several immunomodulatory functions on cells of the adaptive immune 
system (Moharregh-Khiabani et al., 2009). This includes the ability to induce apoptosis of activated 
T cells and the downregulation of the transcription factor NF-κB in T cells, DCs and endothelial 
cells which results in a reduced production of inflammatory cytokines, chemokines and adhesion 
molecules (de Jong et al., 1996; Stoof et al., 2001; Treumer et al., 2003). In EAE and cell culture, 
DMF was described to have neuroprotective functions mediated by the activation of the 
transcription factor Nrf2 which lead to an increased protection of cells against reactive oxygen 
species (ROS) (Linker et al., 2011; Scannevin et al., 2012c). Nevertheless, it is still unknown if DMF 
treatment has any direct effects on the CNS which are not mediated via the modulation of 
peripheral immune cells. 
The present study aimed to analyze if DMF has CNS intrinsic effects independent of the peripheral 
immune system. Therefore, the cuprizone mouse model was used to study the effects of DMF on 
CNS cells, demyelination and remyelination as well as axonal damage. Histological evaluation 
revealed that DMF showed neuroprotective and possibly neuroregenerative effects within the 
CNS. 
In the second part of this study DMF effects were investigated in a B cell-mediated EAE model. So 
far, DMF was only analyzed in mainly T cell-mediated EAE models and direct effects of DMF on 
B cells have not been reported. Clinical, histological and immunological analyses were performed 
to study the DMF effects in this animal model and revealed B cell altering properties of DMF. 
4.1. DMF shows neuroprotective and potentially regenerative effects 
in the cuprizone mouse model 
MS is an inflammatory and demyelinating disease of the CNS with focal lesions in which myelin, 
myelin-forming cells (oligodendrocytes) and axons are damaged (Trapp and Nave, 2008). The 
histopathology of MS is heterogeneous, with lesion patterns characterized by immune-mediated 
demyelination but also patterns which suggest a primary oligodendrogliopathy (Lucchinetti et al., 
2000; Rone et al., 2016). The oral agent DMF has been shown to exert beneficial effects in the 





effects on the peripheral immune system (e.g. reduction of pro-inflammatory T cells and DCs) 
whereas direct effects of DMF on the central nervous system are still controversially discussed 
(Ghoreschi et al., 2011; Litjens et al., 2006; Moharregh-Khiabani et al., 2009; Scannevin et al., 
2012c). We investigated the DMF effects on the CNS in the cuprizone model in which the BBB 
remains intact and an influence of peripheral immune cells can be majorly excluded (Bakker and 
Ludwin, 1987; McMahon et al., 2002). Different time points were examined to analyze the 
treatment effects on oligodendrocyte apoptosis, axonal damage as well as demyelination and 
remyelination. 
4.1.1. DMF exerts neuroprotective effects during short-term cuprizone 
treatment 
One feature of MS lesions is the loss of myelin-producing oligodendrocytes. Oligodendrocytes may 
show signs of apoptotic cell death, e.g. the upregulation of apoptosis-related proteins such as FAS,  
(Dowling et al., 1996; Lucchinetti et al., 2000). Thus, we aimed to analyze if DMF could influence 
the apoptosis of oligodendrocytes induced by cuprizone intoxication. Loss of oligodendrocytes is 
an early event during cuprizone treatment and therefore DMF effects on apoptosis were analyzed 
after one week of cuprizone diet (Figure 2) (Matsushima and Morell, 2001b). The number of 
apoptotic cells was significantly reduced by DMF treatment, which suggested that DMF may have 
a cytoprotective effect on oligodendrocytes (Figure 2). The exact mechanism of cuprizone-induced 
oligodendrocyte apoptosis is still unknown, but several studies suggest that cuprizone provokes 
mitochondrial dysfunction, such as the formation of giant mitochondria, and disturbances of the 
oligodendroglial metabolism which could contribute to the apoptosis of oligodendrocytes (Acs et 
al., 2013; Goldberg et al., 2013; Matsushima and Morell, 2001b). The formation of these 
megamitochondria mainly takes place in hepatic cells but could also be observed in 
oligodendrocytes (Acs et al., 2013; Biancotti et al., 2008). It is considered to be a protective 
mechanism of cells against oxidative stress, since it was demonstrated that mitochondria enlarge 
when exposed to elevated levels of ROS in vitro (Wakabayashi, 2002). These data may suggest that 
the cuprizone-mediated loss of oligodendrocytes could be caused by increased oxidative damage. 
It could already be demonstrated that oligodendrocytes show a high vulnerability to oxidative 
stress (Praet et al., 2014). One factor which contributes to this high vulnerability is the intrinsically 
low amount of glutathione (GSH) in oligodendrocytes, a molecule which is required as an electron 





This enzyme reduces free hydrogen peroxide (H2O2) in order to protect cells from oxidative 
damage. Furthermore, cuprizone intoxication was shown to decrease the GSH content of hepatic 
cells as well as oligodendrocytes and could thereby increase susceptibility of oligodendrocytes to 
oxidative stress (Biancotti et al., 2008). Several in vitro and in vivo studies revealed that DMF can 
protect cells against oxidative damage via an increased activation of Nrf2 and increased 
production and recycling of GSH. Nrf2 elevates gene expression of several detoxification enzymes 
(e.g. GSH-dependent enzymes) and is normally located in the cytoplasm where it is sequestered to 
kelch-like erythroid cell-derived protein 1 (Keap1), a functional inhibitor of Nrf2 (Nguyen et al., 
2009).  Fumaric acid esters (FAEs), including DMF, can bind Keap1 by covalent binding to thiol 
groups and therefore promote the translocation of Nrf2 into the nucleus (Linker et al., 2011; 
Nguyen et al., 2005). A study in 1990 could show that in vivo DMF treatment induces the activity 
of GSH-dependent detoxification enzymes (e.g. NADPH oxidoreductase) in various murine tissues 
(Spencer et al., 1990). In vitro, DMF and its metabolite MMF elevated GSH levels in murine and 
human astrocytes and increased the viability of astrocytes and rat cortical neurons after oxidative 
challenge with H2O2 (Albrecht et al., 2012; Scannevin et al., 2012c). The DMF effect on cell viability 
after oxidative stress challenge was suggested to be Nrf2-dependent, since the effect was lost in 
cells lacking Nrf2. Additionally, in vitro treatment with MMF increased cellular ATP content and 
more importantly, enhanced mitochondrial membrane polarization which can antagonize 
mitochondrial dysfunction (Scannevin et al., 2012c). A recent study showed that in vitro DMF 
treatment increases the levels of antioxidant molecules including carnitine, ascorbic acid and GSH 
in human oligodendrocytes (Huang et al., 2015). Correspondingly, DMF could also protect 
oligodendrocytes against H2O2-mediated oxidative damage. Oxidative stress and mitochondrial 
injury are also assumed to contribute to oligodendrocyte loss in MS pathology (Bradl and 
Lassmann, 2010; Haider et al., 2011). A continuative study confirmed that mitochondrial injury 
occurs in active MS lesions and may contribute to the production of ROS (Fischer et al., 2012). 
Thus, the antioxidant impact of DMF may also exert beneficial effects leading to reduced 
oligodendrocyte loss in MS patients.  
Besides the apoptosis of oligodendrocytes, it was also investigated if DMF influences the number 
of oligodendrocytes including oligodendrocyte precursor cells (Olig2+ cells) and specifically mature 





This study revealed that DMF treatment preserved a higher number of Olig2+ cells whereas the 
number of NogoA+ cells was only slightly increased by DMF treatment at this time point (Figure 3). 
The lowest numbers of Olig2+ cells are observed after 10 days of cuprizone treatment whereas 
fewest numbers of NogoA+ cells are observed on day 21 of cuprizone treatment (Hesse et al., 
2010b). Interestingly, on day 21 numbers of Olig2+ cells start to increase again suggesting a 
recruitment of oligodendroglial progenitor cells (OPCs) even with ongoing cuprizone treatment 
(Matsushima and Morell, 2001b). This phenomenon was also observed in our experiments, where 
Olig2+ cells were decreased compared to NogoA+ cells on day 7 of cuprizone treatment (Figure 3).  
Our data suggest that DMF might exert an early protective effect on oligodendrocytes which are 
majorly affected by cuprizone intoxication, specifically preserving Olig2+ cells.   
Furthermore, DMF also significantly reduced the number of acutely damaged axons compared to 
control treatment, investigated 7 days after cuprizone treatment (Figure 4). Acute axonal damage 
was analyzed by staining for amyloid precursor protein (APP), which is observed at sites of axonal 
injury (Koo et al., 1990). Although cuprizone treatment leads to axonal damage in mice, it is 
assumed that cuprizone has no direct toxic effect on axons and axonal damage is rather a 
secondary event following previous oligodendroglial damage (Irvine and Blakemore, 2006; Mason 
et al., 2001; Stidworthy et al., 2003). In murine EAE, DMF treatment could significantly increase 
axonal density in early and chronic disease stages (Linker et al., 2011; Reick et al., 2014). In a 
model of experimental autoimmune neuritis (EAN), DMF reduced the acute axonal damage in rats 
which correlated with a significant increase of Nrf2 in axons at this time point (Pitarokoili et al., 
2015). Consequently, DMF-mediated Nrf2 activation is thought to lead to a better protection of 
axons. In MS, acute axonal damage mainly occurs during the early stages of disease and  correlates 
with the extent of inflammation (Kuhlmann et al., 2002). Taken together, these data suggest that 
DMF treatment may reduce the acute axonal damage in MS patients by direct CNS effects in 
addition to the known axon-protective effect ascribed to the immunomodulatory mode of action 
of fumarates. 
Cuprizone treatment of mice leads to an increased activation of microglia/macrophages and 
increased number of reactive astrocytes, features which also can be observed in MS lesions 
(Groebe et al., 2009; Hibbits et al., 2012; Hiremath et al., 1998). In our study DMF treatment only 





expressing GFAP (glial fibrillary acidic protein) after 7 days of cuprizone treatment (Figure 4). 
Although it was reported that DMF reduced microglial inflammation in vitro, only mild in vivo 
effects of DMF on the infiltration of macrophages were observed in several EAE or previous 
cuprizone experiments (Linker et al., 2011; Moharregh-Khiabani et al., 2009; Reick et al., 2014; 
Wilms et al., 2010). Therefore, DMF seems to have no major effect on the activation and 
accumulation of microglia/macrophages in these animal models. In contrast, DMF has been shown 
to reduce the number of activated astrocytes in the spinal cord of EAE mice (Linker et al., 2011). 
This observation could suggest that the DMF-induced decrease of astrogliosis is mainly mediated 
by peripheral immunomodulatory effects of DMF.  
To analyze if the DMF effects on oligodendrocyte apoptosis could also be observed at a later time 
point after cuprizone exposure, the number of apoptotic cells and mature oligodendrocytes were 
analyzed after 2 weeks of cuprizone treatment. Since in later stages of cuprizone diet, 
oligodendroglial cell death is independent of caspase 3, apoptotic cells were analyzed by 
morphology (condensed and/or fragmented nuclei) (Hesse et al., 2010b). DMF treatment slightly 
reduced the number of apoptotic cells, but in contrast to day 7 this effect did not reach statistical 
significance (Figure 5). The number of oligodendrocytes (Olig2+ cells) and mature oligodendrocytes 
(NogoA+ cells) was not altered by DMF at this time point (Figure 5). As described above, the 
number of NogoA+ cells decreases with ongoing cuprizone diet, a circumstance which could also 
be observed in this study (Kuhlmann et al., 2002). A possible explanation for the obtained results 
could be the strong toxic impact of cuprizone on oligodendrocytes which might override the DMF 
effect. Nevertheless, a slight reduction of apoptotic oligodendrocytes was still visible after 
2 weeks. Conversely, it is also possible that DMF mainly affects only specific apoptotic mechanisms 
(e.g. caspase 3-dependent cell death) which may mainly occur during the early phase of cuprizone 
treatment and later changes to other cell death mechanism which are unaffected by DMF 
treatment (Kuhlmann et al., 2002).        
Since it is assumed that the cytoprotective effects of DMF could be mainly mediated via the 
activation of Nrf2, a pilot experiment was performed to examine if the DMF effects observed after 
7 days of cuprizone are also Nrf2-dependent. Therefore, DMF effects on the number of apoptotic 
cells were investigated in Nrf2 knock-out (Nrf2 k.o.) mice. In line with other studies, no protective 





suggesting that the observed effects after 7 days of cuprizone treatment may indeed be Nrf2-
dependent (Figure 13) (Linker et al., 2011; Scannevin et al., 2012c). The obtained results further 
support the hypothesis that the neuroprotective effects of DMF could be mainly mediated by 
activation and stabilization of Nrf2. 
4.1.2. DMF treatment increases differentiation and regeneration of 
oligodendrocytes after long-term cuprizone treatment 
To analyze DMF effects on demyelination, mice were fed with cuprizone for 6 weeks which 
induces significant demyelination of the CC (Gudi et al., 2009; Matsushima and Morell, 2001b). 
DMF treatment of mice could only slightly decrease the demyelination occurring in the CC, 
whereas the number of mature oligodendrocytes (NogoA+ cells) was significantly increased by 
DMF (Figure 6, Figure 9). Cuprizone-induced demyelination of the CC peaks at 5 weeks and 
remyelinated axons can already be observed between week 5 and 6 even with ongoing cuprizone 
treatment (Mason et al., 2001). DMF effects on demyelination were also investigated after 
5 weeks of cuprizone exposure, and results were similar to data received after 6 weeks (data not 
shown). The received results are in line with the results of a previous study, where no significant 
effects of DMF on the demyelination of the CC could be observed (Moharregh-Khiabani et al., 
2010). In addition to apoptosis of oligodendrocytes mediated by oxidative stress, cuprizone 
treatment also leads to disturbances of myelin protein synthesis and myelin lipid metabolism 
(Praet et al., 2014). Cuprizone intoxication reduces plasma levels of several amino acids leading to 
the activation of the amino acid response pathway (AAR) which in turn strongly reduces protein 
synthesis (Goldberg et al., 2013). A huge part of the myelin lipid layers consists of phospholipids, 
mainly plasmalogens (Farooqui and Horrocks, 2001). Cuprizone increases the activity of 
plasmalogenase and phospholipase A2 (PLA2), two enzymes which degrade membrane-bound 
plasmalogens and thereby contribute to myelin sheath destruction (Carey and Freeman, 1983). 
DMF treatment was shown to increase phospholipid synthesis by oligodendrocytes in vitro, but 
this effect might not be equally potent in vivo, which could explain the minor DMF effects on 
demyelination (Huang et al., 2015). Nevertheless, higher numbers of mature oligodendrocytes 
were observed under DMF after long-term cuprizone diet. These data suggest that long-term DMF 
treatment could be protective against cuprizone-induced oxidative stress while it may not majorly 
alter the cuprizone-induced metabolic disturbances contributing to myelin destruction. In a 





term cuprizone exposure but DMF effects after short-term cuprizone diet were not investigated at 
all (Moharregh-Khiabani et al., 2009). In our study, DMF treatment increased the number of 
mature oligodendrocytes after long term treatment. Most probably, the higher numbers of OPCs 
after short-term cuprizone exposure resulted in more OPCs that differentiated into mature 
oligodendrocytes. Thereby, it may be assumed that DMF promotes the regeneration and 
differentiation of oligodendrocytes. This DMF-mediated maintenance or increased differentiation 
of oligodendrocytes could potentially be important for MS treatment, since it was described that 
especially in chronic MS lesions OPCs largely fail to mature to oligodendrocytes (Kuhlmann et al., 
2008b). 
4.1.3. Therapeutic DMF treatment shows neuroprotective effects on 
axons 
To investigate how DMF can influence remyelination, mice were fed with cuprizone for 5 weeks to 
induce profound demyelination of the CC. Then the cuprizone diet was stopped and mice were 
therapeutically treated with control or DMF for 3 days. No significant DMF effect on the extent of 
remyelinaton or the number of activated macrophages/microglia in the CC was found (Figure 10, 
Figure 11). Also, the overall number of oligodendrocytes and mature oligodendrocytes were not 
altered by DMF treatment (data not shown). As described above, remyelination already starts 
after 5 weeks, even with ongoing cuprizone exposure (Mason et al., 2001). After cuprizone 
withdrawal, almost complete remyelination can be observed after 4 weeks (Lindner et al., 2008b; 
Torkildsen et al., 2008). Remyelination is accompanied by migration and differentiation of OPCs as 
well as a reduction of activated microglia/macrophages in the CC (Matsushima and Morell, 2001b; 
Stangel and Hartung, 2002). Microglia/macrophage numbers peak in week 3-5 during cuprizone 
treatment (Mason et al., 2001). On the one hand, microglia and macrophages are considered as 
detrimental because of their pro-inflammatory cytokine production, contributing to an increased 
inflammation and damage within the CNS  (Lampron et al., 2015). On the other hand, these 
phagocytic cells are important for the clearance of myelin debris. It could be demonstrated that 
decreased myelin removal by microglia/macrophages can prevent proper remyelination in the 
cuprizone model (Lampron et al., 2015; Skripuletz et al., 2013). DMF treatment could not alter the 
number of microglia/macrophages 3 days after cuprizone removal which could be a possible 
explanation why remyelination was not enhanced by DMF. Another fact which has to be taken 





overridden by this fast process. Thus, the experimental setup used may not be suitable to show 
beneficial treatment effects on remyelination.  
Importantly, DMF treatment significantly reduced the acute axonal damage 3 days after cuprizone 
withdrawal (Figure 11), suggesting a neuroprotective effect of therapeutic DMF application. 
Studies in the cuprizone model demonstrated that axonal damage could still be observed in the CC 
of mice long after remyelination was already completed (Manrique-Hoyos et al., 2012). 
Furthermore, persistent axonal loss despite sufficient remyelination was found after chronic 
cuprizone-mediated demyelination (Lindner et al., 2009). Therefore, therapeutic DMF treatment, 
although not influencing remyelination, could be an important tool to prevent axonal 
degeneration. Axonal loss occurs independent of the course of MS and majorly contributes to the 
development of brain atrophy (Chard et al., 2002; Kalkers et al., 2002). Hence, it is assumed that 
axonal loss leads to the development of permanent neurological deficits and long-term disability 
in MS patients (Ferguson et al., 1997; Grigoriadis et al., 2004; Haines et al., 2011). It was reported 
that axonal degeneration is already present at early stages of the disease highlighting the need of 
a neuroprotective therapy in MS at an early stage (Kalkers et al., 2002). Two recent studies 
demonstrated that especially an early DMF treatment mediates a beneficial effect on brain 
atrophy in MS patients (Dupuy et al., 2016; Kappos et al., 2016). Although, it is still unknown how 
DMF exerts its function on brain atrophy, beneficial effects on axonal damage may contribute to 
therapeutic effects observed in these studies. It is suggested that DMF facilitates mitochondrial 
function which was shown to be disturbed in axons of MS patients (Huang et al., 2015; Su et al., 
2009). Since this mitochondrial dysfunction could contribute to axonal degeneration, a beneficial 
effect of DMF on mitochondria may subsequently reduce axonal damage.  
In conclusion, the CNS intrinsic effects of DMF observed in this study may play an important role 
for the therapy of MS. After one week of cuprizone exposure, mice treated with DMF showed 
higher body weights compared to controls. After six weeks of cuprizone treatment body weights 
between control- and DMF-treated animals were comparable. These results indicate that the 
effects described above are not mediated by a reduced cuprizone intake of DMF mice, perhaps 
due to gastrointestinal side effects, but rather by DMF or its metabolite MMF itself. The latter was 
shown to reach the brain even when the BBB remains intact (Figure 12). In the present study, DMF 





Initially, DMF treatment seems to mainly increase the number of OPCs and is potentially 
promoting their differentiation into mature oligodendrocytes, which were increased after long-
term cuprizone treatment. Furthermore, DMF treatment concurrent to cuprizone intoxication as 
well as applied after cuprizone induced demyelination had occurred (“therapeutic DMF 
treatment”) reduced the acute axonal damage significantly. These results suggest that DMF exerts 
neuroprotective and neuroregenerative effects independent of peripheral inflammation. 
Currently, therapy of MS mainly includes immunomodulatory and immunosuppressive drugs 
whereas neuroprotective or regenerative treatments are basically not available (Stangel, 2008). 
The sole application of immunomodulatory drugs cannot completely prevent CNS injury. Thus, the 
CNS intrinsic effects of DMF observed in this study could therefore be an important therapeutic 
tool for the treatment of MS.  
4.2. DMF treatment shows opposing effects on lymphocytes in B cell-
mediated EAE 
After the investigation of DMF effects within the CNS, we further investigated the DMF effects on 
the peripheral immune system. EAE is a suitable animal model of MS in which immunomodulatory 
drugs, like DMF, can be initially tested for their potential therapeutic effectiveness in MS. The 
effects of DMF have been investigated in mainly T cell-mediated EAE models in which DMF could 
ameliorate the disease course and decreased the overall CNS damage (Linker et al., 2011; Reick et 
al., 2014; Schilling et al., 2006). Furthermore, several studies demonstrated that DMF induces the 
apoptosis of pro-inflammatory T cells, the development of anti-inflammatory dendritic cells and 
reduces the secretion of pro-inflammatory cytokines and chemokines (Ghoreschi et al., 2011; 
Gillard et al., 2015; Litjens et al., 2006; Treumer et al., 2003). The clinical efficacy of rituximab in 
MS patients elucidated that also B cells can majorly contribute to the pathogenesis of MS (Hauser 
et al., 2008b).  Hence, a medication exerting immunomodulatory effects on B cells could be a 
promising medication for MS patients. So far, DMF effects on B cells have been poorly described 
and only two recent studies suggest that DMF also directly influences B cell activation and can 
change the distribution of subpopulations (Lundy et al., 2016; Schulze-Topphoff et al., 2016). We 
investigated the effect of DMF in an EAE model, in which B cells contribute in a more pathogenic 
manner. Clinical, histological and immunological analyses were performed to study the DMF effect 





4.2.1. DMF treatment improves clinic and pathology of EAE mice  
At first it was evaluated how DMF treatment affects clinical parameters like disease severity, 
serum antibody level as well as demyelination and inflammation of the spinal cord in EAE mice. In 
our EAE model, C57BL/6 mice were immunized with a recombinant mouse myelin oligodendrocyte 
glycoprotein (rMOG1-117), which leads to the development of antigen-activated B cells and 
production of antibodies (Ab) directed against MOG (Weber et al., 2010). In this EAE model, B cells 
contribute majorly to the pathogenesis of the disease and support the development of pro-
inflammatory IFNγ- and IL-17-producing T cells. Mice were treated preventively or therapeutically 
with 15 mg/kg bodyweight DMF or control twice a day for 60 or 50 days. Preventive and 
therapeutic DMF treatment could profoundly ameliorate the disease course of mice compared to 
control-treated animals (Figure 15). In the past, DMF was mainly investigated in MOG35-55 peptide 
induced EAE, which is a primarily T cell-mediated model. In contrast to these previous studies, in 
our EAE model therapeutic DMF treatment showed a pronounced effect on disease severity 
whereas previously only slight or no effects were seen in MOG35-55 peptide induced EAE (Kihara et 
al., 2015; Linker et al., 2011). These data suggest that this beneficial effect could be mediated by 
an immunomodulatory impact of DMF on B cells which, different from B cells in MOG35-55 peptide 
induced EAE, substantially promote the disease severity in rMOG1-117 induced EAE. Moreover, 
these results also highlight the importance of appropriate medication dosage since therapeutically 
applied DMF showed no effect when administered twice a day at a concentration of 100 mg/kg 
bodyweight (Kihara et al., 2015). Nevertheless, the impact of preventive DMF treatment was still 
significantly more distinct when compared to therapeutic application of DMF. These results are 
comparable to findings in MOG35-55 peptide induced EAE where preventive DMF treatment also 
considerably improved the EAE course (Kihara et al., 2015; Linker et al., 2011; Reick et al., 2014; 
Schilling et al., 2006). 
Activated B cells can differentiate into plasmablasts and plasma cells which secrete antigen-
specific antibodies (Nutt et al., 2015). Immunization of mice with rMOG1-117 leads to the 
development of anti-MOG antibodies which recently have been shown to play an important role in 
the initiation of CNS demyelinating disease (Kinzel et al., 2016). Therefore, it was interesting to 
analyze DMF effects on the production of antibodies. Serum anti-MOG Ab levels of mice 





p.i. (Figure 16). Neither preventive nor therapeutic DMF treatment significantly decreased the 
serum level of anti-MOG Ab levels. Preventive application of DMF even slightly increased anti-
MOG Ab level when compared to controls. A recent study showed that the immunomodulatory 
agent IFNβ also enhanced serum anti-MOG IgG and IgM antibodies in EAE, but these increased 
antibodies did not correlate with EAE severity and occurred despite clinical benefit (Schubert et 
al., 2015). According to these data, preventive and therapeutic DMF treatment improved EAE 
severity, although auto-antibody levels were not majorly altered. These data suggest that injury of 
the CNS may not be primarily mediated by auto-antibodies in EAE (Schubert et al., 2015).   
Hence, preventive and therapeutic DMF treatment decreased EAE severity, these effects were 
further examined by histology. Demyelination and overall inflammation of the spinal cord was 
profoundly reduced by therapeutic DMF treatment and slightly decreased under preventive DMF 
treatment (Figure 17). In line with previous findings, DMF treatment did not majorly alter T cell 
(CD3+ cell) numbers in the spinal cord (Linker et al., 2011; Reick et al., 2014; Schilling et al., 2006). 
The DMF effects on the number of infiltrating B cells (B220+ cells) were even less pronounced 
when compared to infiltrating T cell numbers. In contrast to preventive DMF treatment, 
therapeutic DMF application significantly decreased the number of infiltrating 
macrophages/microglia (Mac3+ cells). Several studies demonstrated that preventive DMF 
treatment has no effect on the infiltration of microglia/macrophages and also in this study, no 
significant effect could be observed under preventive DMF administration (Linker et al., 2011; 
Reick et al., 2014). These results are comparable to results received in the cuprizone model, where 
DMF did also not influence the accumulation of microglia/macrophages. However, this study is the 
first demonstrating that therapeutic DMF treatment reduced demyelination and inflammation of 
the spinal cord as well as the number of accumulating microglia/macrophages. Thus, it can be 
assumed that the time point of treatment start influences the immunomodulatory effects 
mediated by DMF. In MS, microglia and macrophages are supposed to contribute to CNS injury by 
the production of high amounts of pro-inflammatory cytokines and chemokines as well as ROS 
(Jack et al., 2005). These recent findings lead to the suggestion that DMF treatment of MS patients 





4.2.2. DMF treatment has immunomodulatory effects on peripheral 
B cells and T cells  
The pathogenesis of MS is partly mediated by circulating B and T cells and it was shown that the 
composition and functions of B cell and T cell subsets are altered in MS patients (Jones et al., 
2016). Studies of DMF effects on the adaptive immune system revealed that DMF might mediate a 
shift in T cell subsets towards more anti-inflammatory T cells and could induce the apoptosis of B 
cells and T cells (Ghoreschi et al., 2011; Mrowietz and Asadullah, 2005; Treumer et al., 2003).  To 
analyze how DMF influences the adaptive immune system and thereby improves clinical course of 
EAE and CNS injury, DMF effects on B cells and T cells were investigated in the initial phase of EAE. 
C57BL/6 mice were treated 2 or 7 days prior to immunization until day 12 p.i. It was investigated 
how DMF treatment affects activation, composition of subpopulations and functional properties 
of B cells and T cells. 
4.2.2.1. DMF has anti-inflammatory effects on peripheral T cells 
Several studies in animal models and the observation of inflammatory cells and their effector 
functions in MS lesions led to the majorly accepted hypothesis that the disease is mediated by 
autoreactive T cells which cross the BBB and induce inflammation and damage inside the CNS 
(Fletcher et al., 2010). The EAE model mirrors clinical and pathological features of MS and was 
mainly used to achieve a better understanding of the pathogenesis of MS. Due to the important 
role of T cells in MS and EAE, it was investigated if the beneficial clinical effects of DMF could be 
mediated by an alteration of T cell activation and differentiation. It was reported that DMF induces 
apoptosis of human T cells and could lead to lymphopenia in MS patients (Gold et al., 2012; 
Treumer et al., 2003). In a first experiment it was therefore analyzed if these effects could be 
observed in EAE mice treated with DMF. The frequencies of CD4+ T cells, CD8+ T cells, CD19+ cells 
(B cells) and CD11b+ cells were examined in blood, lymph node and spleen of control- and DMF-
treated mice. DMF treatment significantly reduced the frequency of CD4+ T cells in the blood 
whereas the frequencies of CD8+ T cells, CD19+ cells (B cells) and CD11b+ cells were only slightly 
reduced (Figure 18). These results are comparable to data reported for human peripheral blood 
lymphocyte subsets, where short term DMF treatment led to a decrease of CD4+ T cells (Spencer 
et al., 2015). Conversely, only a slight reduction of CD8+ T cells and CD19+ cells could be observed 





These result may reflect a discrepancy between EAE and MS, since CD8+ T cells do not majorly 
contribute to the pathogenesis of EAE but are numerously found in lesions of MS patients (’t Hart 
et al., 2011). This might explain why circulating CD8+ T cells in EAE mice were not as strongly 
reduced by DMF as in humans. However, the most interesting result was that the frequency of 
CD4+ T cells in lymph node and the frequencies of CD4+ T cells and CD8+ T cells in spleen were 
significantly increased under DMF treatment. These data would suggest that the decrease of T 
cells seen in the blood of MS patients and EAE mice could rather be mediated by reallocation of T 
cells than by DMF-mediated apoptosis. Initial studies of DMF, as a component of the anti-psoriatic 
drug Fumaderm®, demonstrated  a reduction of T cells in the majority of patients (Altmeyer et al., 
1996). A subsequent in vitro study of DMF  seemed to confirm the ability of DMF to mediate 
apoptosis in human T cells (Treumer et al., 2003). An important fact which has to be taken into 
account is that only in vitro treatment with DMF, not its metabolite MMF, induced T cell apoptosis 
and this additionally was solely observed under very high concentrations (Gill and Kolson, 2013). 
No apoptotic effect of DMF was shown under physiologic concentrations which can be 
accomplished by its metabolite MMF in vivo. These data support the hypothesis that DMF and its 
metabolite MMF rather mediate an accumulation of T cells in secondary lymphoid organs and not 
primarily induce the apoptosis of T cells.  
The DMF-mediated accumulation of T cells in lymph node and spleen raised the question of how 
these T cells are activated and which T cell subsets contribute to the high T cell frequencies. To 
address this question a flow cytometric analysis was performed and the activation markers CD69 
and CD25 were measured on CD4+ T cells and CD8+ T cells of control or DMF-treated mice. The 
expression of CD69 and CD25 was profoundly decreased on CD4+ T cells and CD8+ T cells of DMF-
treated mice (Figure 19). CD69 is one of the earliest activation markers and is upregulated on T 
cells after antigen-recognition (Groth et al., 2004). CD25 is the α-chain of the IL-2 receptor. Upon 
T cell activation, CD25 expression is upregulated leading to the creation of a high affinity IL-2 
receptor (Gaffen, 2001). IL-2 is a cytokine which majorly drives T cell differentiation and 
proliferation. Effector T cells show the highest expression of CD69 and CD25 whereas naïve and 
memory T cells only show low or no expression of CD69 and CD25 (Hataye et al., 2006). 
Considering these data, DMF-mediated downregulation of CD69 and CD25 reflects a decreased 





The clinical benefit of DMF could thus be mediated by a suppressing effect on T cells, since 
especially autoreactive effector T cells exacerbate disease severity (Fletcher et al., 2010). 
Additionally, it was studied if DMF alters the expression of the T cell activation marker CD44. 
CD4+ T cells and CD8+ T cells expressing high levels of CD44 (CD44hi) were significantly decreased in 
spleens of DMF-treated mice (Figure 20, Figure 21). This effect was also slightly visible in the 
lymph node of DMF-treated mice. CD44 is an adhesion receptor and enhanced levels of CD44 are 
found on memory cells (Baaten et al., 2010b; Groth et al., 2004). Therefore, CD44 is widely used as 
a “ memory marker” to differentiate naïve from activated and memory T cells (Budd et al., 1987). 
In this study, DMF treatment led to a decrease of CD4+ and CD8+ memory T cells whereas the 
population of naïve T cells remained unaltered. These results suggest that the increased 
population found in lymph node and spleen under DMF treatment is mainly composed of naïve T 
cells rather than of activated/memory T cells (Figure 18). Furthermore, these findings support the 
results concerning the activation status of T cells (CD69/CD25) (Figure 19). Naïve CD4+ T cells show 
already an intermediate expression level of CD44, which explains why within the CD4+ T cell 
population not only CD44low but also CD44int T cells are increased under DMF treatment (Figure 20) 
(Groth et al., 2004). 
Activated CD4+ T cells can differentiate into different subpopulations, such as IFNγ- (Th1), IL-17- 
(Th17) or IL-4/IL-10- (Th2) producing T cells. IFNγ- and IL-17-producing T cells (Th1, Th17 cells) are 
the commonly induced CD4+ T cells in EAE (Fletcher et al., 2010; Kurschus, 2015; O’Connor et al., 
2008). A recent study demonstrated that in MOG35-55 peptide induced EAE, DMF treatment led to 
decreased frequencies of Th1 and Th17 cells (Schulze-Topphoff et al., 2016). Furthermore, it was 
shown that lymphocytes of DMF-treated MS patients produce higher amounts of the cytokines IL-
4 and IL-10, which are mainly produced by Th2 cells suggesting that DMF might mediate a “Th1 to 
Th2 shift” (Gill and Kolson, 2013). Thus, it was interesting to analyze if DMF also alters the 
differentiation of T cells in rMOG1-117 induced EAE model. The frequency of splenic and lymphatic 
Th1 cells was significantly reduced by DMF treatment and Th17 cell frequencies were slightly 
decreased (Figure 22). Importantly, this effect was not due to reduced frequencies of viable 
CD4+ T cells as shown in Figure 22. These results are comparable to previous studies in MOG35-55 
peptide induced EAE where DMF treatment also decreased Th1 and Th17 cells  (Schulze-Topphoff 





development and survival of Th1 cells whereas Th2 and Th17 differentiation seems to be 
independent of CD44 (Baaten et al., 2010b). Consequently, the prominent decrease of Th1 cells 
under DMF treatment could partly be mediated by the DMF-induced downregulation of CD44 
(Figure 20). Conclusively, this would also explain why the DMF effect was more prominent on the 
Th1 population compared to the Th17 population. Th1 and Th17 cells contribute in a large part to 
the pathogenesis of EAE. Thus, a DMF-mediated downregulation of these two cell populations 
could majorly improve the disease course, as it was seen in this study. 
Regulatory T cells (Tregs) play an important role in downregulating or suppressing excessive 
inflammatory responses. In MS patients, the frequency of Tregs is reduced during relapses and 
increases again during remission (Fletcher et al., 2010). A medication enhancing the frequency of 
Tregs could therefore bear a therapeutic benefit. In our EAE model, DMF treatment did not 
majorly alter the frequency of regulatory T cells, although a slight increase could be observed in 
spleens from DMF-treated mice (Figure 23). These data suggest that the induction of Tregs is not 
profoundly altered by DMF treatment and that the clinical effects could be rather mediated by a 
downregulation of pro-inflammatory T cells.   
4.2.2.2. DMF alters T cell proliferation 
The previous ex-vivo experiments revealed that T cell activation and development of pro-
inflammatory T cells (Th1 cells) is reduced in immunized EAE mice treated with DMF (Figures 19-
22). Conferring to these results, a further experiment determined how DMF influences the 
proliferation of T cells when these are stimulated in an antigen-independent manner. Purified 
T cells from naïve C57BL/6 mice, treated with either control- or DMF for 19 days, were stimulated 
with anti-CD3/CD28 in vitro to induce T cell proliferation. Treating T cells with anti-CD3/CD28 
simulates the activation by antigen-presenting cells (Trickett and Kwan, 2003). Ex vivo proliferation 
of CD4+ T cells and CD8+ T cells was significantly diminished when these were previously treated 
with DMF in vivo (Figure 24A-B). A detailed analysis of the proliferation revealed that T cells from 
DMF-treated animals showed lower proliferation rates compared to control-treated animals, 
illustrating that control-treated T cells divided themselves more often upon anti-CD3/CD28 
stimulation. Considering these data, in vivo DMF treatment seems to have an anti-proliferative 
effect on naïve T cells when these are stimulated in vitro. These results are in line with the 





activated/memory T cells. Additionally, it was investigated how in vivo DMF treatment of T cells 
influences their differentiation in vitro. Supernatants of this T cell cultures were collected and the 
amount of secreted IFNγ and GM-CSF was measured by ELISA. Analysis revealed that DMF-treated 
T cells produced significantly less IFNγ and GM-CSF compared to control-treated T cells (Figure 
24C). Taken together, it could be assumed that DMF treatment decreases the differentiation of 
pro-inflammatory Th1 cells by downregulating T cell activation and proliferation. In the recent 
years it could be frequently shown that also GM-CSF producing T cells majorly contribute to 
pathogenesis of EAE and also occur in higher frequencies in MS patients (Codarri et al., 2011; 
Grifka-Walk et al., 2015; Rasouli et al., 2015). Thus, the DMF-mediated downregulation of GM-CSF-
producing T cells could be another effect leading to an improvement of EAE severity. 
In summary, DMF treatment reduced the activation and proliferation of T cells as well as inhibited 
their differentiation into pro-inflammatory effector cells. Fewer frequencies of CD4+ T cells and 
CD8+ T cells were found in the blood of DMF-treated mice, but showed an increased accumulation 
in secondary lymphoid organs. Since DMF decreased the generation of Th1 and Th17 cells, but did 
not increase the frequency of Tregs, it could be assumed that DMF induced the development of 
Th2 cells which could account for the higher frequency of CD4+ T cells. These results would be 
comparable to observations in DMF-treated patients where DMF mediates a “Th1 to Th2 cell shift” 
(Gill and Kolson, 2013). Furthermore, DMF treatment mediates a reduction of memory T cells and 
a relative expansion of naïve T cells, an effect which was also reported for MS patients treated 
with DMF (Gross et al., 2015; Longbrake et al., 2016). DMF treatment similarly decreased the 
activation of CD8+ T cells which can contribute to MS pathogenesis and are numerously found in 
brain lesions of MS patients (Friese and Fugger, 2009; ’t Hart et al., 2011). This overall anti-
inflammatory effect of DMF on T cells could have majorly contributed to the disease improvement 
in rMOG1-117 induced EAE. In addition, the DMF effects observed in this study might be a hint on 
how DMF mediates the beneficial effects seen in MS therapy.   
4.2.3. DMF-treated B cells are more potent antigen-presenting cells 
Immunization with MOG35-55 peptide directly activates autoreactive CD4+ T cells via an interaction 
with the MHC-II complex-bound peptide on APCs without the need to of internal processing 
(Slavin et al., 2001; Weber et al., 2010). In contrast, in rMOG1-117 induced EAE the native MOG has 





CD4+ T cells (Slavin et al., 2001). This leads to the generation of pathogenic B cells, which recognize 
the MOG-protein via their B cell receptor and subsequently activate MHC-II restricted CD4+ T cells 
(Weber et al., 2010).  
In this study, it was investigated how DMF treatment influences these pathogenic B cells and if the 
clinical benefits seen in this model could be mediated by an anti-inflammatory effect on 
pathogenic B cells. Similar to the analysis of T cells, first experiments examined DMF effects on the 
B cell activation at day 12 p.i. Data evaluation revealed that in contrast to T cells, DMF treatment 
rather increased the activation of B cells primarily by enhancing the MHC-II expression on 
lymphatic B cells (Figure 25). Although the co-stimulatory molecules CD80, CD86 and CD40 were 
not significantly altered their expression was slightly increased on lymphatic B cells of DMF-
treated mice. The expression levels of the activation markers CD69, CD25 and Fas were not 
modified by DMF treatment (Figure 26). It could therefore be assumed that DMF primarily 
influences antigen-presenting and co-stimulatory functions of B cells and not so much the 
expression of activation markers. Additionally, no significant DMF-mediated enhanced expression 
of MHC-II could be observed at day 60 after immunization (data not shown). This would suggest 
that either MHC-II expression on B cells is not further inducible at this time point or that DMF 
influences MHC-II especially during the early and acute phase of EAE, where immune cells become 
mainly activated in the periphery. MHC-II is important for the cognate interaction between B cells 
and T cells (Scholl and Geha, 1994). The peptide/MHC-II-complex is recognized by the T cell 
receptor (TCR) of CD4+ T cells and leads to the activation of antigen-specific T cells (Charles A 
Janeway et al., 2001). These activated T cells increase the expression of co-stimulatory molecules 
and secret cytokines and chemokines which subsequently stimulate the proliferation and 
differentiation of B cells. Taken together, it could be assumed that the DMF-mediated increase of 
MHC-II expression on B cells promotes the activation and proliferation of B cells and T cells and 
conclusively this data suggests that DMF has opposing effects on B cells and T cells. Nevertheless, 
there was no enhanced expression of activation markers on B cells under DMF treatment leading 
to the suggestion that DMF-mediated dampening effects on T cells did not result in increased 
B cell activation. Naïve B cells require pronounced stimulating signals from CD4+ T cells or their 
respective antigen itself to proliferate and differentiate. Since DMF treatment decreased the 





activation signal for T cells but that these T cells were not fully activated due to the 
immunomodulatory effects of DMF. Deductive, no effective T cell help was provided for antigen-
presenting B cells which therefore did not become fully activated. Another hypothesis could be 
that DMF mediated a shift towards a more regulatory phenotype of B cells and following the initial 
activation of B cells, demonstrated by enhanced MHC-II expression, induced the development of 
anti-inflammatory B cells which can also be observed in individual DMF-treated MS patients (Li et 
al., 2017). This assumption would also explain why DMF treatment improved the course of EAE 
although it rather promotes activation of B cells by increasing their antigen-presenting properties.   
The increased activation of B cells raised the question how DMF influences individual 
subpopulations of B cells. B cell subsets can be defined by their expression of CD21 and CD23, 
which differs on specific B cell subtypes (Shen and Fillatreau, 2015). Both markers are highly 
expressed on transitional B cells whereas for example follicular B cells show a lower expression of 
CD21 (Meyer-Bahlburg et al., 2008). In this study CD21hi CD23+ B cells were referred to as 
transitional B cells and CD21int CD23+ B cells were referred to as follicular B cells. In vivo DMF 
treatment induced a shift in B cell subsets towards fewer transitional and more follicular B cells in 
isolated splenic cells (Figure 27). The frequency of immature B cells (CD21- CD23-) in the bone 
marrow was not altered suggesting that DMF-mediated changes only occur in the periphery 
(Figure 27). The observed results indicate that DMF treatment may promote the differentiation of 
B cells towards a population which exerts a potent antigen-presenting function, the follicular B 
cells. Inside secondary lymphoid organs like the spleen, naïve follicular B cells present antigens to 
CD4+ T cells which results in an immune response to the presented antigen (Allman and Pillai, 
2008). 
Furthermore, DMF effects were analyzed on the frequency of immature naïve B cells, mature 
naïve B cells, memory B cells, regulatory B cells, germinal center B cells and antigen-activated 
B cells (Figure 28). Although DMF did not significantly alter any of these B cell phenotypes, higher 
frequencies of antigen-activated B cells and lower frequencies of immature naïve B cells could be 
observed in DMF-treated, rMOG1-117 immunized animals. Antigen-activated B cells express CD69, 
CD80 and high levels of MHC-II, which supports the hypothesis that DMF contributes to the 
activation of B cells via an increased induction of MHC-II and co-stimulatory molecules such as 





mature naïve B cells in the spleen, indicating that DMF treatment could moderately facilitate B cell 
maturation. On one side, these findings lead to the assumption that the beneficial clinical effects 
of DMF may not be B cell-mediated since DMF rather promotes the generation of antigen-
activated B cells which could contribute to the pathogenesis of the disease. On the other side, 
these activated B cells could also exert a more anti-inflammatory and/or regulatory function which 
could mediate an improvement of the disease (Ray and Basu, 2014). The latter hypothesis can be 
supported by the slightly increased frequency of regulatory B cells which were observed in DMF-
treated animals (Figure 28). 
As a first functional analysis, it was investigated if DMF can influence the antigen-recognition and 
antigen-binding of B cells. Therefore, in vivo control- and DMF-treated B cells were isolated and ex 
vivo incubated with a fluorescent-labeled rMOG1-117 and the frequency B cells which were able to 
recognize and bind rMOG1-117 could be analyzed via flow cytometry. DMF treatment did not alter 
the frequency of rMOG-binding B cells compared to controls (Figure 29). This suggest that DMF did 
not influence the antigen-recognition and antigen-binding abilities of B cells and that DMF 
therefore does not alter the antigen-affinity of the B cell receptor.   
Another functional analysis focused more on the antigen-presenting function of B cells. Thus, B 
cells purified from control- or DMF-treated immunized mice were co-cultured with naïve CFSE-
labeled 2D2 T cells, which have a transgenic T cell receptor specific for MOG, and were stimulated 
with rMOG1-117 (Bettelli et al., 2003). Antigen-presenting function of these B cells was then 
analyzed via the extent of T cell proliferation. In this setting, T cell proliferation was significantly 
increased when these were co-cultured with DMF-treated B cells compared to control (Figure 30A-
B). A more detailed quantification revealed that the frequencies of T cells with low, intermediate 
and high proliferation rate were increased by DMF-treated B cells when compared to controls. 
Additionally, cultured DMF-treated B cells also showed a slightly higher expression of MHC-II 
compared to control-treated B cells (Figure 30C). These data support the hypothesis that DMF 
treatment can lead to the development of more potent antigen-presenting B cells which caused 
the increased proliferation of T cells. These findings are also in line with the previous results 
illustrating an increased MHC-II expression and enhanced frequencies of follicular and antigen-
activated B cells under DMF treatment. To receive a first hint if these DMF-treated B cells exert 





was measured in a similar co-culture. When compared to control-treated B cells, DMF-treated B 
cells did not alter the frequency of IFNγ-producing T cells (Figure 31). Thus, it could be assumed 
that the decrease of IFNγ-producing T cells found ex vivo under DMF treatment might not be a B 
cell-mediated effect. Furthermore, these data suggest that either DMF does not promote the 
development of a more anti-inflammatory and/or regulatory B cell phenotype or that this effect is 
not strong enough to exert a B cell-mediated immunomodulatory effect on T cell differentiation in 
vitro.  
In conclusion, the present study could show that DMF treatment significantly ameliorated the 
clinical course of rMOG1-117 induced EAE and that demyelination and inflammation in the spinal 
cord were profoundly decreased. Furthermore, DMF decreased T cell activation and the frequency 
of pro-inflammatory Th1 cells which majorly contribute to the disease pathogenesis. This anti-
inflammatory effect did not seem to be profoundly mediated by B cells since DMF-treated B cells 
did not influence Th1 cell differentiation in vitro. It could therefore be assumed that DMF either 
directly affects T cell differentiation or that this effect is mediated by other immune cells. A study 
of Litjens et al. could demonstrate that the DMF-metabolite MMF alters the maturation and 
polarization of dendritic cells (DCs) resulting in a decreased generation of Th1 cells (Litjens et al., 
2004b, 2006). This effect may have contributed to the amelioration of rMOG1-117 induced EAE, 
since DCs are the most potent APCs which promote the antigen-specific activation of 
encephalitogenic T cells (Ganguly et al., 2013). Surprisingly, DMF treatment increased MHC-II 
expression on B cells and increased their ability to present antigen. In contrast to results in B cell-
mediated EAE, DMF treatment decreased MHC-II expression on B cells in MOG35-55 peptide 
induced EAE suggesting that DMF may exerts opposing immunomodulatory effects on B cells with 
(rMOG EAE) or without (MOG-peptide EAE) major pathogenic functions (Schulze-Topphoff et al., 
2016). The increased ability of these B cells to present antigen via MHC-II furthermore promoted 
the proliferation of T cells. It is still unclear if and how these potent antigen-presenting B cells 
could influence the T cell differentiation. Although, Th1 cell differentiation was not reduced by 
DMF-treated B cells, B cells may induce differentiation of Th2 cells, which can exert anti-
inflammatory functions. This would explain the increased population of CD4+ T cells found in 
lymph node and spleen of DMF-treated mice which was neither composed of Th1, Th17 cells nor 





could be found under DMF treatment, it could be shown that B cells with regulatory function are 
found in DMF-treated MS patients (Lundy et al., 2016). Conclusively, the B cell-activating functions 
mediated by DMF could thereby contribute to an improvement of the disease. 
4.3. DMF altered B cell properties in MS patients 
DMF treatment of rMOG1-117 immunized mice ameliorated the disease course but seemed to 
simultaneously increase the activation of B cells, demonstrated by an increased expression of 
MHC-II and partly also co-stimulatory molecules. To analyze if this increased MHC-II expression 
could be found on human B cells, PBMCs from non-treated and DMF-treated MS patients 
(treatment duration ≥ 6 months) were analyzed by flow cytometry. Evaluation of data revealed 
that human B cells isolated from DMF-treated MS patients showed an increased MHC-II expression 
when compared to controls (Figure 32). These data support the results found in our EAE model 
(Figure 25). Furthermore, similar findings could be demonstrated in a study which showed that 
B cells isolated from DMF-treated MS patients showed an enhanced MHC-II expression (Staun-
Ram et al., Poster 185 ISNI 2016). Recent studies reported that DMF treatment could induce an 
anti-inflammatory B cell phenotype which contributes to the regulation of the peripheral immune 
system (Li et al., 2017; Lundy et al., 2016). Although DMF treatment increases the MHC-II 
expression on B cells and increases their ability to present antigens, these B cells might still be able 
to possess anti-inflammatory and/or regulatory properties and thereby exert beneficial functions. 
Nevertheless, DMF seems to have an activating function on B cells which should be taken into 
account when choosing proper medication for individual MS patients. For example, it could 
recently be demonstrated in rMOG1-117 induced EAE, B cells which reoccur after anti-CD20 
treatment show enhanced pro-inflammatory properties (Linda Feldmann, group internal 
communication, data not published). It could therefore be assumed that DMF may not be the 







The present study provides evidence that DMF exerts axon- and cytoprotective effects and 
promotes regeneration of mature oligodendrocytes independent of the peripheral immune 
system. These DMF effects were potentially mediated by an increased activation of the 
transcription factor Nrf2 which leads to an enhanced protection of cells against oxidative stress. 
No significant effects were observed on demyelination and remyelination, but may also be due to 
limitations of this animal model.  It could be interesting to analyze the DMF effects in a modified 
cuprizone model where the phase of extensive demyelination is prolonged and the process of 
remyelination is delayed (Bai et al., 2016).   
In the second part of this study it could be show that DMF treatment improved clinical and 
pathological parameters of an EAE model with involvement of pathogenic B cells. Although DMF 
could profoundly decrease the activation and differentiation of pro-inflammatory T cells, it 
enhanced the antigen-presenting function of B cells. This study could not completely elucidate 
which B cell phenotype is promoted by DMF treatment and subsequently which T cell phenotype 
is induced by these B cells. Further analysis could focus on phenotyping these DMF-treated B cells 
and elucidate if they promote a pro- or anti-inflammatory milieu. One experimental approach to 
study the DMF-mediated B cell phenotype could be a B cell transfer experiment. Therefore, 
control- or DMF-treated CD20k.o. B cells could be transferred into immunized, B cell-depleted WT 
animals and clinical parameters such as EAE onset, severity and incidence could indicate if these B 
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